

CLINTON OFFICE

1307 E. Townsend Rd. Saint Johns, MI 48879-9036 (989) 224-2195

GRATIOT OFFICE

151 Commerce Dr. Ithaca, MI 48847-1627 (989) 875-3681

MONTCALM OFFICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

BOARD OF HEALTH:

Bruce DeLong
David Pohl

George Bailey Timothy Gay Phil Kohn Adam Petersen

MID-MICHIGAN DISTRICT HEALTH DEPARTMENT (MMDHD)

BOARD OF HEALTH

REGULAR MEETING

at

Montcalm Office, Stanton, Michigan Conference Rooms A & B

Wednesday, July 26, 2023 9:00 a.m.

AGENDA

We take action to protect, maintain, and improve the health of our community.

Pledge of Allegiance

- A. AGENDA NOTES, REVIEW, AND REVISIONS:
 - 1.
- B. CONSENT ITEMS:
 - Meeting Minutes
 - a. Michigan Association for Local Public Health (MALPH) Board of Directors Meeting held June 12, 2023 Included.
 - b. Mid-Michigan District Board of Health Regular Meeting held June 28, 2023 Included.
 - Mid-Michigan District Board of Health Finance Committee Special Meeting held July 12, 2023 Included
 - 2. Communications
 - a. MDHHS HIV Prevention Award Letter Included.
- C. PUBLIC COMMENTS:
- D. BRANCH OFFICE EMPLOYEES:
- E. COMMITTEE REPORTS:

- 1. Finance Committee George Bailey, Chairperson
 - a. MMDHD's Expenses for June 21 through July 14,2023 Included.
 - b. MMDHD's Monthly Balance Sheet, Revenue and Expenditure Report for July 2023 Included.
 - c. FY 23/24 Proposed Budget and Narrative Included.
 - d. FY 23/24 Proposed Fees Included.
 - 1. Environmental Health (EH)
 - 2. Community Health & Education Division (CHED)
- 2. Personnel Committee David Pohl, Chairperson
 - a. Teamsters Negotiations Updates
 - b. MNA Reopener
 - c. Personnel Committee Meeting scheduled for July 26,2023 at 11:00 a.m. Montcalm Office
- 3. Program Committee Phil Kohn, Chairperson

a.

- 4. Mid-Central Coordinating Committee David Pohl
 - a. Mid-Central Meeting July 17, 2023 Handout
- F. MEDICAL DIRECTOR'S REPORT: Jennifer E. Morse, MD, MPH, FAAFP Included.
 - 1. Air Quality
- G. HEALTH OFFICER'S REPORT: Mari E. (Liz) Braddock
 - 1. Agreements signed None.
 - 2. FY 22/23 Quarterly Service Report (QSR), Third Quarter (April 1 through June 30,2023) Included
 - 3. Health Officer Report Gratiot Office Lighting Strike Included
- H. OLD BUSINESS:

1.

I. NEW BUSINESS:

- Emerging Issues
- J. <u>LEGISLATIVE ACTION:</u>

1.

3.

- K. <u>INFORMATIONAL ITEMS:</u> **Included.**
 - 1. Mid-Michigan District BOH Action Items, June 2023 -Included
 - 2. Staffing Report -Included
- L. RELATED NEWS ARTICLES AND LINKS: https://www.mmdhd.org/2023-board-of-health/
 1.
- M. <u>AGENCY NEWSLETTERS: https://conta.cc/3JSE079</u> -Included.



CLINTON OFFICE

1307 E. Townsend Rd. Saint Johns, MI 48879-9036 (989) 224-2195

GRATIOT OFFICE

151 Commerce Dr. Ithaca, MI 48847-1627 (989) 875-3681

MONTCALM OFFICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

BOARD OF HEALTH:

Bruce DeLong David Pohl George Bailey Timothy Gay Phil Kohn Adam Petersen

Board of Health (BOH) Synopsis of Actions Needed

July 26,2023 Regular Meeting

Item A. 1.	AGENDA NOTES, REVIEW, AND REVISIONS
Motion to	approve the Agenda as presented.
	_
Item B. 1., 2. & 3.	CONSENT ITEMS (MEETING MINUTES & COMMUNICATIONS)
Motion to	accept Meeting Minutes B. 1. a., B. 1. b. and B. 1. c. and place on file.
Item E. 1. a.	EXPENSES FOR JUNE 21 THROUGH JULY 14, 2023
Motion to	approve payment of the Mid-Michigan District Health Department's Expenses for
June 21, th	rough July 14, 2023, totaling \$663,084.52.
Item E. 1. b.	BALANCE SHEET, REVENUE AND EXPENDITURE REPORT FOR JUNE 2023
Motion to	approve and place on file the Balance Sheet, Revenue and Expenditure Report for
June 2023.	
Item E. 1. c.	FY 23/24 PROPOSED BUDGET AND NARRATIVE
Motion to	approve the FY 23/24 Proposed Budget and Narrative.
Item E. 1. d.	FY 23/24 PROPOSED AGENCY FEES
Motion to	approve FY 23/24 Agency Fees as proposed.
Item F.	MEDICAL DIRECTOR'S REPORT; AIR QUALITY
Motion to	adopt the BOH Monthly Healthy Living Recommendations for July as proposed.
Motion to	accent and place the Medical Director's Papert on file
iviotion to	accept and place the Medical Director's Report on file.
Item G.	HEALTH OFFICER'S REPORT
Motion to	accept the Health Officer's report and place on file.

MICHIGAN ASSOCIATION FOR LOCAL PUBLIC HEALTH

(MALPH)

Board of Directors Meeting Minutes June 12, 2023

I. Call to Order

The meeting was called to order at 9:04am by Jimena Loveluck, President.

II. Roll Call

A quorum was present.

Jurisdictions Represented: Allegan [Angelique Joynes], Barry-Eaton [Milea Burgstahler], Bay [Joel Strasz], Benzie-Leelanau [Dan Thorell], Berrien [Guy Miller], Branch-Hillsdale-St. Joseph [Rebecca Burns], Calhoun [Eric Pessell], Central Michigan [Steve Hall], Chippewa [Jill Schaefer], Delta-Menominee [Mike Snyder], Detroit [Christina Floyd], District 2 [Denise Bryan], District 10 [Kevin Hughes], District 4 [Denise Bryan], Grand Traverse [Wendy Hirschenberger], Huron [Tip MacGuire], Ingham [Anne Barna, Brenda Gray], Ionia [Chad Shaw], Jackson [Kristin Pluta], Kalamazoo [Jim Rutherford], Kent [Adam London], Lapeer [Kathy Haskins], Livingston [Matt Bolang, Rebecca Leach], Luce-Mackinaw-Alger-Schoolcraft [Nick Derusha], Macomb [Andrew Cox], Midland [Fred Yanoski], Mid-Michigan [Liz Braddock], Monroe [Kim Comerzan], Northwest Michigan [Dan Thorell], Ottawa [Adeline Hambley], Saginaw [Christina Harrington], Shiawassee [Larry Johnson], St. Clair [Liz King]Tuscola [Amanda Ertman], VanBuren/Cass [Danielle Persky]Washtenaw [Jimena Loveluck], Wayne [Avani Sheth], Western UP [Kate Beer].

Others Present: Administrative Officers Forum, [Holly Karpovich], Health Education and Promotion Forum, [Jill Keast], Environmental Health Forum, [Tony Drautz], Nurse Administrators Forum, [Christie Clement], Physician's Forum, [Delicia Pruitt], EGLE, [Dana DeBruyn, Sara Pearson, Ian Smith], LARA, [Larry Horvath], MAC, [Dwight Washington], MDARD, [Tim Slawinski, Becky Vought], MDHHS, [Molly Cotant, Laura de la Rambelje, Adrian Zeh], PAA, [Becky Bechler],

Staff: Norm Hess, Jodie Shaver. Gwen Tithof

III. Approve Agenda

Motion by W. Hirschenberger, support by R. Burns to approve the agenda. Motion carried.

IV. Approve Minutes of the May 8, 2023 Meeting

Motion by M. Bolang, support by N. Derusha to accept the May 8, 2023 meeting minutes. Motion carried.

V. Public Affairs Associates Report

B. Bechler reported still waiting for the state budget. Rep. Whitwer (House Appropriations chair) thinks they will have a recommendation in the next day or two, and hopefully their version will be in front of the conference committee by next week. Rep. O'Neil is in our corner, trying to push for the full \$30 million in the House budget. The goal is to pass the budget by the end of June, before summer break. N. Hess will share the letter sent to legislators regarding the ELPHS funding.

VI. Partner Updates

- D. DeBruyn (EGLE) reported EGLE met with Rep. Skaggs on June 7th to work on Sanitary Code bill. Rep. Skaggs will continue to meet with stakeholders and there is no concrete timeline except will aim to move forward in the fall. EGLE is still reviewing RFPs for contractors to handle the failing septic system loan program. Private well sampling portal is almost finished. EGLE is expecting to provide free private well sampling by July. Comments on PFAS regulation have been submitted to the EPA and will be publicly available soon. Seven (7) counties in Michigan will be offered water sampling for manganese at no cost.
- B. Vought and T. Slawinski (MDARD) reported they are still waiting on Food Law updates. MDARD is sending Multi-jurisdictional outbreak guidance to MALEHA food committee before finalization. Two (2) more days have been added for Outbreak Ready training. Some spots will be filled from the wait list and registration will open on Wednesday for the remaining spots. They are still working on replacing Lisa Hainstock and will hopefully have the position filled by the end of the month.
- L. de la Rambelje (MDHHS) reported there was a meeting last week to discuss accreditation feedback. The state legislature continues with budget negotiations, with \$14 million for share-match still in the House. MDHHS is still waiting on official word from the CDC that the infrastructure funding will not be affected by federal deficit grant callbacks. The understanding is that if you have a notice of award (which MDHHS does), that funding will not be rescinded. However, if the multi-year grant is distributed in yearly awards, those future years' funding may be affected. MDHHS is waiting for a supplemental bill to allocate the funding from the CDC, as well as some old federal funds from 2020 and 2021.
- L. Horvath (LARA) reported there has been some team reorganization, but state licensing still falls under Larry. The new organization chart can be found at https://www.michigan.gov/lara/-

/media/Project/Websites/lara/about/Folder1/LARAs Organization Chart.pdf?rev=bcecfc 67967046d3b6652aad92006c6e&hash=25959A4178454E98A36DC8F5DFAC93C4

Please reach out to Larry first, and he'll connect you with the correct department/contact. Larry will bring someone from CRA to the next MALPH Board meeting to present and answer questions regarding cannabis/marijuana oversight.

VII. Officer Updates

J. Loveluck- President sent a written president's report prior to the meeting.

N. Hess presented the April 2023 financials on behalf of C. Scrimger-Secretary / Treasurer. A motion by N. Derusha, support by C. Shaw to approve the April 2023 financials as presented. Motion carried.

J. Shaver reported the MDARD communications trainings have concluded, and we have hopes that these trainings will be offered again in the fall. The MPPHC planning committee has completed selections for concurrent, keynote, and poster presentations. The registration brochure is expected to be released in late July. The annual awards information, the overnight room reservation link, and the partner commitment form are all on the MALPH website. The MPPHC planning committee will be holding a student networking session at the MPPHC. The registration information has been opened for the new leaders workshop, funded by the CJS grant with MMDHD. The workshop will be at Treetops Resort on August 8th and applicants must have a recommendation from their immediate supervisor. Registration for the health officer retreat in September will be coming out later this month. The 2024 MALPH Day at the Capitol will be on April 10, 2024. A save the date will be sent out. It is now time to form the nominations committee for the FY2024 MALPH Executive Committee. If you are interested in volunteering for the nominations committee, or you would like to run for a position on the executive committee, please contact J. Loveluck.

N. Hess reported the staffing and services inventory, originated through CJS funding and managed by Barry-Eaton District Health Department has been transferred to MALPH. MALPH would like to get a small group of volunteers to review and provide input on survey questions. We anticipate launching the survey in late summer. The state budget discussions have \$30 million in Senate bill; \$14 million in House bill for Essential Local Public Health Services funding. The chair of House HHS Appropriations Subcommittee got information from House Fiscal Agency that said \$14 million would be enough to reach pandemic-level contributions from locals. MALPH submitted a letter on June 9th stating they need to use pre-pandemic contributions levels. Review sessions wrapping up this week for the CPH cohort. We expect participants to begin taking their exams mid-summer. Average attendance for each session was about 25 participants. Please let N. Hess know if

Average attendance for each session was about 25 participants. Please let N. Hess know if any of your staff members pass their test. LHA has allocated another \$200,000 from the Prevent Block Grant to support wellness activities for local public health. MALPH will be granting mini grants to LHDs again. MALPH submitted Alchemer License requests for all LHDs who responded that they were interested in extending their license through September 2023. We will invoice those who indicated that they have another source of

funding to pay for the license. It was most efficient for us to pay the Academy of Science bill all at once. There have been many improvements and additions to the software. If you want to sign up again, just let us know. In FY 24, CDC workforce funds can be used to pay for your \$1,000 annual license. MALPH is monitoring HB 4328/SB 247 (G. Filler/S. McCann), which expands access to alcohol sales in sporting venues on college campuses.

VIII. Forum Reports

<u>Admin Forum</u>- H. Karpovich reported the Billing forum had a breakout meeting. The Admin forum is constructing the annual administrators' conference. Please send your admin staff as it very beneficial.

MALEHA- T. Drautz reported MALEHA continues working on reviewing Sanitary Code.

<u>HEP-</u> J. Keast reported the policy and advocacy committee is becoming more popular, especially on SUD and tobacco/menthol topics. The first annual in-person meeting is in Gaylord at the end of July.

<u>NAF-</u> C. Clemente reported the NAF retreat was last month. NAF continues discussing Kindergarten Oral Health.

<u>MAPPP</u>- D. Pruitt reported they had a MiCelerity presentation at their last meeting. MAPPP continues to discuss COVID updates amongst the end of the emergency.

IX. Public Comments / Announcements / Requests for Future Agenda Items

N. Hess will not be at the July Board meeting because he will be at the NACCHO 360 conference in Denver. Contact N. Hess if you will also be going to NACCHO 360.

X. Adjournment

The meeting adjourned at 10:11am.



CLINTON OFFICE

1307 E. Townsend Rd. Saint Johns, MI 48879-9036 (989) 224-2195

GRATIOT OFFICE

151 Commerce Dr. Ithaca, MI 48847-1627 (989) 875-3681

MONTCALM OFFICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

BOARD OF HEALTH: Bruce DeLong George Bailey Phil Kohn
David Pohl Timothy Gay Adam Petersen

MID-MICHIGAN DISTRICT HEALTH DEPARTMENT(MMDHD) BOARD OF HEALTH REGULAR MEETING

at

Gratiot Office, Ithaca, Michigan

Wednesday, June 28, 2023 9:00 a.m.

MINUTES

We take action to protect, maintain, and improve the health of our community.

Members Present: Adam Petersen, Chairperson; George Bailey, Vice Chairperson; Bruce DeLong,

David Pohl, and Timothy Gay

Members Absent: Phil Kohn

Staff Present: Mari E. (Liz) Braddock, Health Officer; Melissa Selby, Director of Administrative

Services; Jennifer E. Morse, MD, MPH, FAAFP, Medical Director; Lonnie Smith,

Director of Environmental Health (EH); Krishna Santana, Board Secretary

Staff Absent: None

Guests: None

Adam Petersen, Chairperson, called the Regular Meeting of the Mid-Michigan District Board of Health (BOH) to order at 9:00 a.m. on Wednesday, June 28, 2023, at the Gratiot Office of the MMDHD, Ithaca, Michigan.

The Pledge of Allegiance was led by A. Petersen.

A. AGENDA NOTES, REVIEW, AND REVISIONS:

DeLong requested to add an Agenda item to New Business, Item 1, Administrative Day for July 3, 2023.

Motion made by G. Bailey and seconded by D. Pohl to approve the Agenda as revised. Motion carried.

B. CONSENT ITEMS:

- 1. Meeting Minutes
 - a. Michigan Association for Local Public Health (MALPH) Board of Directors Meeting held May 8, 2023
 - b. Mid-Michigan District BOH Regular Meeting held May 24, 2023

Motion made by B. DeLong and seconded by G. Bailey to accept Meeting Minutes B. 1. a. and b. and place on file. Motion carried.

- 2. Communications
 - a. WIC Resident Service Programs
 - b. Rural Health Carry-forward CDC OT21-2103
 - c. HRA Award Letter 23-24
 - L. Braddock went over the communication explaining each item and how the funds are used within the district.

Motion made by B. Delong second by D. Pohl to accept and place on file the communications.

- C. PUBLIC COMMENTS: None
- D. BRANCH OFFICE EMPLOYEES: -None
- E. COMMITTEE REPORTS:
 - 1. Finance Committee George Bailey, Chairperson
 - a. MMDHD's Expenses for May 6 through June 16, 2023

Motion made by G. Bailey and seconded by B. DeLong to approve payment of the MMDHD's Expenses for May 6 through June 16,2023 totaling \$773,509.58. Motion carried.

b. MMDHD's Monthly Balance Sheet, Revenue and Expenditure Report for May 2023

Motion made by G. Bailey and seconded by D. Pohl to accept the Balance Sheet, Revenue and Expenditure Report for May 2023 and place on file. Motion carried.

- c. Access Control System
 - M. Selby explained there is a need to purchase additional commercial doors, this will ensure the doors automatically closes. There is also a need to purchase additional latch protectors for doors that have large gaps between the door and the latch, this will ensure the door cannot be pried open. The funding for the additional \$4,000.00 will be covered by the Rural Health Grant.

Motion made by G. Bailey and seconded by B. DeLong to allocate \$4,000.00 for the access control system. Motion carried.

- 2. Personnel Committee David Pohl, Chairperson
 - Teamsters T214 Negotiations Update The scheduled meeting for June 28,2023 has been canceled by Teamsters and a new meeting set for July 21,2023.
 - MNA Reopener This has not been scheduled at this time, awaiting the results from the Teamsters meeting.

Motion made by B. DeLong supported by G. Bailey to accept and place on file the Personnel Committee report.

- 3. Program Committee Phil Kohn, Chairperson No Report.
- 4. Mid-Central Coordination Committee David Pohl

Upcoming Mid-Central Committee meeting Monday, July 17,2023, 10:30 a.m. at Central Michigan District Health Department, 2012 E. Preston Ave, Mt. Pleasant. L. Braddock and D. Pohl will attend the Mid-Central Coordination Committee meeting.

- F. MEDICAL DIRECTOR'S REPORT: Jennifer E. Morse, MD, MPH, FAAFP
 - 1. Decline in Routine Vaccinations
 - J. Morse gave an overview of her report and explained the decrease in vaccinations as well as the importance of being vaccinated and keeping up to date on those vaccinations. She told of the differences from state to state in reasons for waivers. She recommends continuing to support vaccinations and if there are any question concerning vaccines please consult a trusted source she indicated websites available for this information. She also recommended to pause and interpret your emotional response before sharing social media concerning these health issues as false information can be easily spread.

There was a discussion about the long-term effects of measles and if there are any campaigns encouraging vaccinations, J. Morse said yes there are multiple campaigns however there are still an increasing amount of vaccination waivers being requested.

Motion made by B. DeLong and seconded by G. Bailey to adopt the BOH Monthly Healthy Living Recommendations for July as proposed and accept and place the Medical Director's Report on file. Motion carried.

- G. <u>HEALTH OFFICER'S REPORT:</u> Mari E. (Liz) Braddock
 - 1. Agreement Signed

One agreement was signed for our bathing beach monitoring program.

2. Michigan's Guide to Public Health for local Governing Entities – https://accreditation.localhealth.net/wp-content/uploads/2023/06/Public Health Guide Final-Digital-Accessible-6.23.pdf

L. Braddock indicated this guide is available at the link provided, we have requested hard copies however they have not been received.

3. Food License Update

Food Licenses were due April 30,2023 however we have three locations that have not submitted the application and payment, Howard City Lanes, Alma College Concession Stand and Tommy's Pizza. At this time fees are being accumulated for late submission, the last of which will be in September at that time enforcement will begin. MMDHD's objective is to have every food establishment in the district licensed.

4. Health Officer Report

L. Braddock gave an overview of her report explaining the increase in animal bites and encounters, this includes a rising number of wildlife encounters; she expressed the importance of avoiding contact with animals in the wild. She also reminded us that the law requires all animal bites be reported to local Animal Control and the Health Department. L. Braddock said yesterday, June 27, 2023, was National HIV Testing Day, MMDHD offered free walk-in rapid HIV tests at the Clinton County Office. She also went over the air quality problems encountered by Michigan at this time and indicated the website has been updated with links to help track the air quality and how it is impacting lives.

Motion made by G. Bailey and seconded by D. Pohl to accept the Health Officer's Report and place it on file. Motion carried.

H. OLD BUSINESS:

1. Statewide Septic Code Update -

L. Braddock explained the statewide septic code is still being discussed and it may become more of an issue in October, MMDHD will continue to monitor any progress in the event we may need to update our district's septic code.

I. NEW BUSINESS:

1. July 3, 2023 – Administrative Day

DeLong proposed Monday, July 3,2023 to be an administrative day for the MMDHD employees.

Motion made by B. DeLong and second by G. Bailey to grant an administrative day Monday, July 3, 2023, to the MMDHD employees. Motion Carried.

2. Emerging Issues – Harmful Algae Blooms

L. Smith stated we have faced with this issue for the last few years, this year being the first we have the capability of rapid testing when a harmful algae bloom is suspected. To date this year we have already had three lakes in the district with harmful algae bloom complaints: Park Lake, Second Lake and Lake Geneva. When a lake tests positive advisories are issued, the advisory indicates humans and animals should stay out of the lake. The Environmental Health Department will continue to monitor these lakes and any other lakes

in our district that may have harmful algae bloom complaints.

J. <u>LEGISLATIVE ACTION:</u> None

K. INFORMATIONAL ITEMS:

- 1. Mid-Michigan District BOH Action Items, May 2023
- 2. Staffing Report
- L. RELATED NEWS ARTICLES AND LINKS: https://www.mmdhd.org/2023-board-of-health/
 - 1. Eye on opioids, *The Daily News*, June 6,2023
 - Income guidelines for WIC Program increased; additional Michigan families may qualify, *Gratiot County Herald*, June 8, 2023
 - 3. Septic standoff, The Daily News, June 9, 2023
 - 4. Rabies, animal bites and wild animal encounters, The Daily News, June 13,2023

AGENCY NEWSLETTERS:

https://conta.cc/3PfqMF2

There being no further business to come before the Board, G. Bailey made a motion to adjourn seconded by B. DeLong. Motion carried. The meeting was adjourned at 9:48 a.m.

Respectfully Submitted,

Krishna Santana, Board Secretary For Adam Petersen, Chairperson

Mid-Michigan District Board of Health



CLINTON OFFICE

1307 E. Townsend Rd. Saint Johns, MI 48879-9036 (989) 224-2195

GRATIOT OFFICE

151 Commerce Dr. Ithaca, MI 48847-1627 (989) 875-3681

MONTCALM OFFICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

BOARD OF HEALTH:	Bruce DeLong	George Bailey	Phil Kohn
	David Pohl	Timothy Gay	Adam Petersen

Mid-Michigan District Health Department (MMDHD)

BOARD OF HEALTH

SPECIAL FINANCE COMMITTEE MEETING

Gratiot Office, Ithaca, Michigan

Wednesday, June 12, 2023, 8:00 a.m.

MINUTES

We take action to protect, maintain, and improve the health of our community.

Members Present: George Bailey (Chair), Bruce DeLong and Adam Petersen

Members Absent: None

Other Board

Members Present: None

Staff Present: Mari E. (Liz) Braddock, Health Officer; Lonnie Smith, Director of Environmental

Health (EH); Sarah Doak, Director of Community Health and Education Division

(CHED); Melissa Selby, Director of Administrative Services

Staff Absent: None

Guests: None

G. Bailey called the Special Finance Committee Meeting of the Mid-Michigan District Board of Health (BOH) to order at 8:00 a.m., on Wednesday, June 12, 2023, at the Gratiot Office of the Mid-Michigan District Health Department (MMDHD), Ithaca, Michigan.

A. FY 23/24 Proposed Draft Budget and Narrative

Motion made by A. Petersen to recommend the BOH approve FY 23/24 Proposed Budget and Narrtive. Motion seconded by B. DeLong. Motion carried.

- B. FY 23/24 Proposed Agency Fees
 - 1. Community Health and Education Division (CHED) Fees

MPH, FAAFP

2. Environmental Health (EH) Fees

WWW.MMDHD.ORG — LIZ BRADDOCK, RS, MS
Health Officer

JENNIFER MORSE, MD,

Motion made by A. Petersen and seconded by B. DeLong to recommend the BOH approve the FY 23/24 Proposed Fees for the Community Health and Education Division and the Environmental Health Division. Motion carried.


C. County Appropriation

County Appropriations were made available to the board for review.

There being no further business to come before the Finance Committee, the meeting adjourned at 8:35 a.m.

Respectfully Submitted,

Liz Braddock, Acting Board Secretary for George Bailey, Finance Committee Chair Mid-Michigan District Board of Health





STATE OF MICHIGAN

GRETCHEN WHITMER
GOVERNOR

DEPARTMENT OF HEALTH AND HUMAN SERVICES LANSING

ELIZABETH HERTEL DIRECTOR

July 11, 2023

Liz Braddock Health Officer Mid-Michigan District Health Department Administrative Offices 615 N. State St. Stanton, MI 48888

Dear Ms. Braddock:

The Michigan Department of Health and Human Services, Bureau of HIV and STI Programs (BHSP), HIV/STI Prevention Section, is pleased to announce our intent to award Mid-Michigan District Health Department (Mid-Michigan) with \$20,000 to support **HIV Prevention** for the period of October 1, 2023 through September 30, 2024.

The specific services funded at Mid-Michigan are: CTR.

The source of funds is shown in the table below. Funding is contingent upon MDHHS receiving anticipated state and federal funds, as well as approval of the budget and work plan.

Funding Source	Allocation
Federal	\$0
Non-Federal	\$20,000
Total Award	\$20,000

Please enter the budget in EGrAMS when notified it is ready for entry. All contracts must be fully executed by September 30, 2023.

To ensure you receive important BHSP communications and are able to submit contract amendment requests your organization's authorized official and program manager must be appropriately registered in the BHSP's contract management and communications system: SHOARS. Click here to register or update your information. https://www.michigan.gov/mdhhs/keep-mi-healthy/chronicdiseases/hivsti/shoars.

If you have any questions regarding this letter, please email <u>MDHHS-HIVSTIOperations@michigan.gov</u>. BHSP looks forward to working with your program.

Sincerely,

Amy S. Peterson, Manager HIV/STI Prevention Section



MONTHLY EXPENSES FOR June 17, 2023 - July 14, 2023

TOTA	AL	\$ 663,084.52
EV 2010	7/14/2023	\$ 374,965.49
EV 2009	6/30/2023	\$ 286,350.44
EV 2008	6/21/2023	\$ 1,768.59



Expense Voucher # 2008		6/20/2023
<u>Payroll</u>		
	Direct Deposit Payroll	\$ 1,768.59
TOTAL		\$ 1.768.59



Expense Voucher #	2009	 6/30/2023
<u>Payables</u>		
<u>Payroll</u>	108304 - 108328 Acumatica Checks & ACH	\$ 113,474.65
	Ameriprise NBS	\$ 100.00
	MERS 457	\$ 1,907.00
	MERS Defined Benefit - Employee	\$ 4,357.02
	Nationwide	\$ 2,180.00
	EFT Payroll Tax	
	Federal	\$ 34,028.11
	State	\$ 5,295.09
	Direct Deposit Payroll	\$ 117,933.86
	Direct Deposit HSA	\$ 7,074.71
TOTAL		\$ 286,350.44

AP Payment Register

Account	Description						
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108304	Closed	6/30/2023	ALPH01	ALPHA FAMILY CENTER	0.00	200.00
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		JULY2023		CLINICS IN JUL	Y 200.00 USD	0.00	200.00
						Document Total:	200.00
						Payment Method Total:	200.00
						Cash Account Total:	200.00
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108305	Closed	6/30/2023	AMAZON01	AMAZON CAPITAL SERVICES	0.00	116.87
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		1Y9R-1PKQ-4		SIGN HOLDERS		0.00	116.87
						Document Total:	116.87
						Payment Method Total:	116.87
						Cash Account Total:	116.87
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108306	Closed	6/30/2023	BROM01	BROMBERG & ASSOCIATES	0.00	57.23
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		22183		MAY TRANSLAT	TIC 57.23 USD	0.00	57.23
						Document Total:	57.23
						Payment Method Total:	57.23
						Cash Account Total:	57.23
		FOR AP					
CASH AP	CASH ACCOUNT	IONA					
CASH AP Doc. Type	CASH ACCOUNT Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
			Date 6/30/2023	Vendor CDWG01	Vendor Name CDW GOVERNMENT, INC.	Doc. Balance 0.00	Orig. Doc. Amount 801.28
Doc. Type CHECK	Payment Ref.	Status					
Doc. Type CHECK Doc. Type	Payment Ref. 108307	Status Closed	6/30/2023		CDW GOVERNMENT, INC. Original Amount Currency	0.00	801.28
Doc. Type CHECK Doc. Type	Payment Ref. 108307	Status Closed Vendor Ref.	6/30/2023	CDWG01	CDW GOVERNMENT, INC. Original Amount Currency	0.00 Discount Taken	801.28 Amount Paid
Doc. Type	Payment Ref. 108307	Status Closed Vendor Ref.	6/30/2023	CDWG01	CDW GOVERNMENT, INC. Original Amount Currency	0.00 Discount Taken 0.00	801.28 Amount Paid 801.28

CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amoun
CHECK	108308	Closed	6/30/2023	CENT02	CENTRAL MICHIGAN DIST HEALTH DEPARTMENT	0.00	5,340.40
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		MAY2023		MD FOR MAY	5,340.46 USD	0.00	5,340.46
						Document Total:	5,340.40
						Payment Method Total:	5,340.4
						Cash Account Total:	5,340.4
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amoun
CHECK	108309	Closed	6/30/2023	CLIN01	CLINTON COUNTY ADMINISTRATION/ACCOUNTING	0.00	1,966.6
CHECK	100309		0/30/2023	CLINOT	CENTON COUNTY ADMINISTRATION/ACCOUNTING	0.00	1,300.0
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		AC-2032-061		JULY RENT	1,966.67 USD	0.00	1,966.6
						Document Total:	1,966.6
						Payment Method Total:	1,966.6
						Cash Account Total:	1,966.6
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amour
CHECK	108310	Closed	6/30/2023	CLIN02	CLINTON COUNTY RESA	0.00	17,843.6
							,
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		20230430		3Q2023 HRA	17,843.67 USD	0.00	17,843.6
						Document Total:	17,843.6
						Payment Method Total:	17,843.6
						Cash Account Total:	17,843.6
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amoun
CHECK	108311	Closed	6/30/2023	ENVI01	ENVIRO-MASTER	0.00	84.00
OHLOR	100011	Glosea	0/00/2020	LIVIOI	ENVINO MAGTER	0.00	04.0
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Pai
BILL		GRR117106		MONTCALM RE	S1 84.00 USD	0.00	84.0
						Document Total:	84.0
						Payment Method Total:	84.0
						Cash Account Total:	84.0
CASH AP	CASH ACCOUNT	FOR AP					
Dag T:	Doumer-4 Def	Otati	Data	Vanda -	Vandan Nama	Data Balan	Only Dec Ass
Doc. Type CHECK	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amoun
CHECK	108312	Closed	6/30/2023	FRIE01	FRIEDLAND INDUSTRIES, INC.	0.00	320.0
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Pai
BILL		6676		CONFIDENTIAL	SI 320.00 USD	0.00	320.0
						Document Total:	320.00
						Payment Method Total:	320.00
						Cash Account Total:	320.0

CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108313	Closed	6/30/2023	GRAT01	GRATIOT AREA CHAMBER OF COMMERECE	0.00	120.00
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		19572	-	2023 DUES	120.00 USD	0.00	120.00
						Document Total:	120.00
						Payment Method Total:	120.00
						Cash Account Total:	120.00
CASH AP	CASH ACCOUNT	FOR AP					
Dec Time	Dovement Bof	Status	Data	Vandor	Vanday Nama	Dec Balance	Orie Dec Amount
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance 0.00	Orig. Doc. Amount
CHECK	108314	Closed	6/30/2023	HEDG01	HEDGEROW SOFTWARE LTD.	0.00	6,000.00
Doc. Type	Branch	Vendor Ref.	Description	1000001105110	Original Amount Currency	Discount Taken	Amount Paid
BILL		1232		4Q2023 LICENS	E 6,000.00 USD	0.00	6,000.00
						Document Total:	6,000.00
						Payment Method Total:	6,000.00
						Cash Account Total:	6,000.00
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108315	Closed	6/30/2023	INSP01	INSPIRATION STUDIO DESIGNS	0.00	93.75
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		3387		5X7 POSTCARE	OS 93.75 USD	0.00	93.75
						Document Total:	93.75
						Payment Method Total:	93.75
						Cash Account Total:	93.75
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108316	Closed	6/30/2023	MCKE01	MCKESSON MEDICAL	0.00	393.17
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		20744194	2000p	LANCET,NEEDL		0.00	393.17
						Document Total:	393.17
						Payment Method Total:	393.17
						Cash Account Total:	393.17
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108317	Closed	6/30/2023	MERC01	MERCK SHARP & DOHME LLC	0.00	1,574.40
	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	Branch	7016969692	Description	HEP A MMR VA	CC 675.79 USD	0.00	675.79
BILL	Branch		Description	HEP A MMR VA		0.00 0.00	675.79 898.61
Doc. Type BILL BILL	Branch	7016969692	Description		CC 675.79 USD	0.00	675.79

CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108318	Closed	6/30/2023	MERI01	MERIDIAN	0.00	978.08
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		63547		BLOOD LEAD	TES 978.08 USD	0.00	978.08
						Document Total:	978.08
						Payment Method Total:	978.08
						Cash Account Total:	978.08
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108319	Closed	6/30/2023	MISD01	MISDU - FRIEND OF COURT	0.00	83.91
	100010	0.0000	0,00,2020			5.55	30.0
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		06302023		6/30/23 EMPL	OYE 83.91 USD	0.00	83.91
						Document Total:	83.91
						Payment Method Total:	83.91
						Cash Account Total:	83.91
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108320	Closed	6/30/2023	MUTU01	MUTUAL OF OMAHA	0.00	5,383.19
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		G000BZQV		JULY LIFE & E		0.00	5,383.19
					.,,,,,,	Document Total:	5,383.19
						Payment Method Total:	5,383.19
						Cash Account Total:	5,383.19
CASH AP	CASH ACCOUNT	FOR AP					
Dog Type	Dovment Bef	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
Doc. Type CHECK	Payment Ref. 108321	Closed	6/30/2023	PATA01	PATAGONIA HEALTH INC	0.00	42,253.08
CHECK	100321	Closed	0/30/2023	PATAUT	PATAGONIA HEALTH INC	0.00	42,255.00
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
DRADJ		9871	•	CREDIT FOR		0.00	-11,420.76
BILL		9798		6/28/23-6/27/2	4 SL 53,673.84 USD	0.00	53,673.84
						Document Total:	42,253.08
						Payment Method Total:	42,253.08
						Cash Account Total:	42,253.08
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108322	Closed	6/30/2023	PETT01	PETTY CASH FUND - ADMINISTRATION	0.00	85.86
	100022	J.0360	O. OO! EUEU	. 21101			
Doc. Type	Branch	Vendor Ref.	Description	DICT:: 1 ==	Original Amount Currency	Discount Taken	Amount Paid
BILL		06142023		DISTILLED WA	ATEI 85.86 USD	0.00	85.86
						Document Total:	85.86
						Payment Method Total:	85.86
						Cash Account Total:	85.86

D	Daymagt Dof	04-4	Data	Vanda:	Vanday Nama	Dec Dele	Only Don Asset 1
Doc. Type CHECK	Payment Ref. 108323	Status Closed	Date 6/30/2023	Vendor RICO01	Vendor Name RICOH USA INC	Doc. Balance 0.00	Orig. Doc. Amount 99.00
CHECK	100323	Closed	6/30/2023	RICOUT	RICOR USA INC	0.00	99.00
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		1097463194		INTERFACE UNI	T 99.00 USD	0.00	99.00
						Document Total:	99.00
						Payment Method Total:	99.00
						Cash Account Total:	99.00
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108324	Closed	6/30/2023	SANO01	SANOFI PASTEUR INC	0.00	741.87
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		920684014		RABIES VACCIN	E 741.87 USD	0.00	741.87
						Document Total:	741.87
						Payment Method Total:	741.87
						Cash Account Total:	741.87
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108325	Closed	6/30/2023	STAP01	STAPLES	0.00	18.81
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		3539993790	•	CBO OFFICE SU		0.00	18.81
						Document Total:	18.81
						Payment Method Total:	18.81
						Cash Account Total:	18.81
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108326	Closed	6/30/2023	STAT04	STATE OF MICHIGAN-LAB	0.00	231.20
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		20230601-27	•	LABS	34.50 USD	0.00	34.50
BILL		20230601-21		LAB	11.50 USD	0.00	11.50
BILL		20230601-22		LABS	23.00 USD	0.00	23.00
		20230601-9		LABS	162.20 USD	0.00	162.20
BILL							
BILL						Document Total:	231.20
BILL						Document Total: Payment Method Total:	231.20 231.20

CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108327	Closed	6/30/2023	VERT01	VERTILOCITY	0.00	28,645.40
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		31008357		MAY UKG READ	Y 959.00 USD	0.00	959.00
BILL		31007452		6/9/23-6/8/24 ACL	JI 27,686.40 USD	0.00	27,686.40
						Document Total:	28,645.40
						Payment Method Total:	28,645.40
						Cash Account Total:	28,645.40
CASH AP	CASH ACCOUNT	FOR AP					
Doc. Type	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	108328	Closed	6/30/2023	WOOD01	WOOD SARAH	0.00	42.75
Doc. Type	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL		06102023		6/6-6/10 CONTRA	42.75 USD	0.00	42.75
						Document Total:	42.75
						Payment Method Total:	42.75
						Cash Account Total:	42.75
					Doc. Type	Count	Amount Paid (USD)
					Check	25	113,474.65
						25 0	113,474.65
					Check		
					Check Prepayment	0	113,474.65 0.00



Expense Voucher #2010

Payables 108329 - 108360 Acumatica Checks & ACH \$ 125,129.25 **Payroll** Ameriprise NBS 100.00 **MERS 457** \$ 1,907.00 \$ MERS Defined Benefit - Employee 4,527.26 2,180.00 Nationwide **EFT Payroll Tax** Federal 39,508.30 State 5,735.49 MERS Defined Benefit - Employer 67,043.09 Jun-23 **Direct Deposit Payroll** \$ 121,543.29 Direct Deposit HSA 6,986.01 <u>Fees</u> Huntington e-Banking fee Jun-23 \$ 326.84 **Huntington Bank Interest** Jun-23 \$ (21.04)**TOTAL** \$374,965.49

7/14/2023

AP Payment Register

Account	Currency	Description						
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001861	108329	Closed	7/14/2023	ADAM01	ADAMS OUTDOOR ADVERTISING OF MICHIGAN	0.00	4,600.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002967		0860983	·	DIGITAL ADVER		0.00	1,100.00
BILL	002968		0861006		4 POSTER ADVE	EF 2,900.00 USD	0.00	2,900.00
BILL	002969		0860908		4 POSTER ADVE	EF 600.00 USD	0.00	600.00
							Document Total:	4,600.00
							Payment Method Total:	4,600.00
							Cash Account Total:	4,600.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001864	108330	Closed	7/14/2023	AMAZON01	AMAZON CAPITAL SERVICES	0.00	170.01
511 2 511	001001	10000	0.0004	.,	7 4117 22 5110 1		5.55	110101
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
DRADJ	003008		CR 1LGG-6Y9	1-4VR7	CD BOOKS	-185.43 USD	0.00	-185.43
BILL	002964		17NJ-N7L9-49	PL	AVERY PRINTAE	3L 19.99 USD	0.00	19.99
BILL	002965		1FYW-VFJ1-R	4FP	ACRYLIC SIGN (CF 33.45 USD	0.00	33.45
BILL	003004		16P7-HDP7-G	CMJ	ACRYLIC SIGN H	1C 20.99 USD	0.00	20.99
BILL	003005		1XWR-RH6W-	3NV3	CD BOOKS	281.01 USD	0.00	281.01
							Document Total:	170.01
							Payment Method Total:	170.01
							Cash Account Total:	170.01
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001839	108331	Closed	7/14/2023	CDWG01	CDW GOVERNMENT, INC.	0.00	6,639.18
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002963		KD37147		KEYSTONE JAC		0.00	38.10
BILL	002974		ZR00366988		APRIL CISCO VO		0.00	685.57
BILL	003000		KK65055		JEN E. SURFACI		0.00	1,667.29
BILL	003001		KL96977		LISA SMITH, ABI		0.00	1,635.56
BILL	003002		KK15053		YEARLINK WIRE		0.00	1,011.38
BILL	003002		KK09433		MS MEETING RO		0.00	1,351.28
BILL	003007		ZR00361526		JUNE 2023 WEB		0.00	250.00
DILL	000007		21100001020		0011L 2020 WLD	200.00 000	Document Total:	6,639.18
							Payment Method Total:	6,639.18
							Cash Account Total:	6,639.18
							Ousii Account Total.	0,009.10

CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001840	108332	Closed	7/14/2023	CENT02	CENTRAL MICHIGAN DIST HEALTH DEPARTMENT	0.00	8,045.14
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002999		JUNE 2023		MD FOR JUNE	8,045.14 USD	0.00	8,045.14
							Document Total:	8,045.14
							Payment Method Total:	8,045.14
							Cash Account Total:	8,045.14
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001841	108333	Closed	7/14/2023	COHL01	COHL, STOKER & TOSKEY, P.C.	0.00	780.00
CHECK	001641	100333	Ciosea	7/14/2023	CONLUI	CORL, STOKER & TOSKET, P.C.	0.00	760.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002970		54591		APRIL LEGAL	780.00 USD	0.00	780.00
							Document Total:	780.00
							Payment Method Total:	780.00
							Cash Account Total:	780.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001842	108334	Closed	7/14/2023	CONT01	CONTROL SOLUTIONS, INC.	0.00	299.00
OHEOR	001042	10000-	010000	1714/2020	33,4101	CONTROL GOLD HORO, INC.		200.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002998		CS257523		CALIBRATIONS	299.00 USD	0.00	299.00
							Document Total:	299.00
							Payment Method Total:	299.00
							Cash Account Total:	299.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001843	108335	Closed	7/14/2023	DRAY01	DRAYTON AUTOMATIC DOOR, LLC	0.00	278.12
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002996		3316		EH GBO DOOR F	RE 278.12 USD	0.00	278.12
							Document Total:	278.12
							Payment Method Total:	278.12
							Cash Account Total:	278.12
CASH AP	USD	CASH ACCOUNT	FOR AP					
Dog Turas	Dof Number	Downert Def	Status	Data	Vander	Vandar Nama	Dec Beleve	Orig Dan America
Doc. Type CHECK	Ref. Number 001844	Payment Ref. 108336	Status	7/14/2023	Vendor EATO01	Vendor Name EATON RESA	Doc. Balance 0.00	Orig. Doc. Amount 3,183.99
CHECK	UU 10 44	100330	Closed	111412023	EATOUT	LATON RESA	0.00	3,103.99
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description	000000 55110 5	Original Amount Currency	Discount Taken	Amount Paid
BILL	002988		008274		3Q2023 DRUG F	R 3,183.99 USD	0.00	3,183.99
							Document Total:	3,183.99
							Payment Method Total:	3,183.99
							Cash Account Total:	3,183.99

Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amoun
CHECK	001845	108337	Closed	7/14/2023	FIRS01	FIRST NATIONAL BANK OMAHA	0.00	1,716.64
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paic
BILL	002924		CREDIT CARI	06/12D	LUFKIN OPEN RE	E 28.99 USD	0.00	28.99
BILL	002951		06/15 CC		TICK GRANT BRY	Y. 568.16 USD	0.00	568.10
BILL	002990		0609 JUNE 20	23	SPEEDWAY GAS	229.00 USD	0.00	229.0
BILL	002991		8712 JUNE 20	23	TIGERCONNECT	359.54 USD	0.00	359.5
BILL	002992		2593 JUNE 20	23	CONDOLENCES.	.C 530.95 USD	0.00	530.9
							Document Total:	1,716.6
							Payment Method Total:	1,716.6
							Cash Account Total:	1,716.64
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amoun
CHECK	001846	108338	Closed	7/14/2023	FORE01	FORESTRY SUPPLIERS INC	0.00	393.50
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002961		419274-00	-	AUGER FOR IAN	E 369.00 USD	0.00	369.00
BILL	002966		419274-00-1		AUGER	24.50 USD	0.00	24.50
							Document Total:	393.50
							Payment Method Total:	393.5
							Cash Account Total:	393.50
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig Doc Amoun
Doc. Type CHECK	001870	108339	Closed	7/14/2023	GREE05	GREENVILLE ROTARY CLUB	0.00	Orig. Doc. Amoun
CHECK	001070	100339	Cioseu	7714/2023	GREEUS	GREENVILLE ROTART CLUB	0.00	100.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002995		07072023		REFUND STFU P	PE 180.00 USD	0.00	180.00
							Document Total:	180.00
							Payment Method Total:	180.00
							Cash Account Total:	180.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amoun
CHECK	001847	108340	Closed	7/14/2023	HOSP03	HOSPITAL NETWORK HEALTHCARE SERVICES	0.00	419.18
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002971		87380	•	JUNE MEDICAL V		0.00	419.18
							Document Total:	419.18
							Payment Method Total:	419.18
							Cash Account Total:	419.18

CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001848	108341	Closed	7/14/2023	JETS01	JETS SPEED PRINTING	0.00	118.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002972		46118		GRAD CARDS	118.00 USD	0.00	118.00
							Document Total:	118.00
							Payment Method Total:	118.00
							Cash Account Total:	118.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
0,1011,1	002	0/10/1/10/00/1/1	10171					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001863	108342	Closed	7/14/2023	K2SCI01	K2SCIENTIFIC	0.00	5,444.88
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002997		0018677-IN		GBO VACCINE	FR 5,444.88 USD	0.00	5,444.88
							Document Total:	5,444.88
							Payment Method Total:	5,444.88
							Cash Account Total:	5,444.88
CASH AP	USD	CASH ACCOUNT	FOR AP					
Dec Time	Def Number	Downant Daf	Status	Date	Vendor	Vendor Name	Doc. Balance	Oria Dec America
Doc. Type CHECK	Ref. Number 001849	Payment Ref. 108343	Status Closed	7/14/2023	KROL01	KROL COMMUNICATIONS, INC.	0.00	Orig. Doc. Amount 3,200.00
CHECK	001649	100343	Ciosea	7/14/2023	KROLUT	RROL COMMUNICATIONS, INC.	0.00	3,200.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002994		1350021795		MAY-SEPT 202	3 N 3,200.00 USD	0.00	3,200.00
							Document Total:	3,200.00
							Payment Method Total:	3,200.00
							Cash Account Total:	3,200.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
D T	Def Neverber	Dayway and Daf	04-4	D-4-	Manadan.	Was day Name	Bas Balanca	Orie Des America
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name MAGELLAN DIAGNOSTICS	Doc. Balance	Orig. Doc. Amount
CHECK	001850	108344	Closed	7/14/2023	MAGE01	MAGELLAN DIAGNOSTICS	0.00	2,026.54
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	003006		63925		LEADCARE II A	NA 2,026.54 USD	0.00	2,026.54
							Document Total:	2,026.54
							Payment Method Total:	2,026.54
							Cash Account Total:	2,026.54
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001851	108345	Closed	7/14/2023	MCKE01	MCKESSON MEDICAL	0.00	1,312.77
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002962		20771976		LANCETS	1,312.77 USD	0.00	1,312.77
					- · -	,	Document Total:	1,312.77
							Payment Method Total:	1,312.77
							Cash Account Total:	1,312.77
							oush Account Total.	1,012.77

CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001852	108346	Closed	7/14/2023	MICH10	MICHIGAN MUNICIPAL RISK MANAGEMENT AUTHORITY	0.00	67,379.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002975		M0001022 20	23	LIABILITY GENE	R 62,879.00 USD	0.00	62,879.00
BILL	002976		R0001022 202	23	LIABILITY RETE	N 4,500.00 USD	0.00	4,500.00
							Document Total:	67,379.00
							Payment Method Total:	67,379.00
							Cash Account Total:	67,379.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001853	108347	Closed	7/14/2023	MISD01	MISDU - FRIEND OF COURT	0.00	83.91
CHECK	001053	100347	Ciosea	1/14/2023	MISDUT	MISDO - FRIEND OF COURT	0.00	03.91
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description	7/4 / /00 = 1 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 /	Original Amount Currency	Discount Taken	Amount Paid
BILL	003010		07142023		7/14/23 EMPLOY	Æ 83.91 USD	0.00	83.91
							Document Total:	83.91
							Payment Method Total:	83.91
							Cash Account Total:	83.91
CASH AP	USD	CASH ACCOUNT	FOR AP					
Dan Tura	Def Number	Down out Dof	Ctatus	Data	Vandan	Vandan Nama	Dec Balance	Orie Dec America
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001867	108348	Closed	7/14/2023	MOTZ01	MOTZ HOMES INC	0.00	51.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002973		08222022		REFUND OVERF	PA 51.00 USD	0.00	51.00
							Document Total:	51.00
							Payment Method Total:	51.00
							Cash Account Total:	51.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
		•						
CHECK	001854	108349	Closed	7/14/2023	NATI05	NRFSP ENVIROMENTAL HEALTH TESTING LLC	0.00	550.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002989		INV134782		9583542-1 22 FC	OC 550.00 USD	0.00	550.00
							Document Total:	550.00
							Payment Method Total:	550.00
							Cash Account Total:	550.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001855	108350	Closed	7/14/2023	PETT01	PETTY CASH FUND - ADMINISTRATION	0.00	90.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002977		06292023		REIMBURSE GB	O 90.00 USD	0.00	90.00
							Document Total:	90.00
							Payment Method Total:	90.00
							Cash Account Total:	
							Cash Account Total:	90.00

CHECK 001862 108351 Closed 7/14/2023 PUBL01 PUBLIC SECTOR CONSULTANTS Doc. Type Ref. Number Branch Vendor Ref. Description Original Amount Currency Discount NV5638 #3 CONSULTING 2,241.00 USD Document Total:	Balance Orig. Doc. A 0.00 2 t Taken Amou 0.00 2
Doc. TypeRef. NumberBranchVendor Ref.DescriptionOriginal Amount CurrencyDiscount CurrencyBILL002979INV5638#3 CONSULTING (\$ 2,241.00 USD)Document Total:	t Taken Amou
BILL 002979 INV5638 #3 CONSULTING : 2,241.00 USD Document Total:	
Document Total:	0.00 2
Berman Made at 1	2
Payment Method [*]	Total: 2
Cash Account Total	al: 2
CASH AP USD CASH ACCOUNT FOR AP	
Doc. Type Ref. Number Payment Ref. Status Date Vendor Vendor Name Doc. E	Balance Orig. Doc. A
CHECK 001856 108352 Closed 7/14/2023 RICO01 RICOH USA INC	0.00
Doc. Type Ref. Number Branch Vendor Ref. Description Original Amount Currency Discount BILL 002980 5067602832 JUNE COPIES 815.41 USD	t Taken Amou
BILL 002980 5067602832 JUNE COPIES 815.41 USD Document Total:	0.00
Payment Method 1	
Cash Account Tot	
Cash Account for	ai.
CASH AP USD CASH ACCOUNT FOR AP	
Doc. Type Ref. Number Payment Ref. Status Date Vendor Vendor Name Doc. E	Balance Orig. Doc. A
CHECK 001857 108353 Closed 7/14/2023 STAT01 STATCOURIER	0.00 2
Doc. Type Ref. Number Branch Vendor Ref. Description Original Amount Currency Discoun	
BILL 002993 1019-3208 JUNE COURIER S 2,267.00 USD	0.00 2
Document Total:	2
Payment Method ²	
Cash Account Tot	al: 2
CASH AP USD CASH ACCOUNT FOR AP	
<u>,, </u>	Balance Orig. Doc. A
CHECK 001866 108354 Closed 7/14/2023 TOTA03 TOTAL ENERGY SYSTEMS LLC	0.00
Doc. Type Ref. Number Branch Vendor Ref. Description Original Amount Currency Discoun	t Taken Amou
BILL 002981 INV101058 6/23/23 GENERAT 403.00 USD	0.00
Document Total:	
Payment Method	Total:
Cash Account Tot	al:
CASH AP USD CASH ACCOUNT FOR AP	
**	Balance Orig. Doc. A
CHECK 001858 108355 Closed 7/14/2023 VERI01 VERIZON	0.00 5
Doc. Type Ref. Number Branch Vendor Ref. Description Original Amount Currency Discoun	t Taken Amou
BILL 002982 9938044611 6/24-7/23 CELL PF 5,312.06 USD	0.00 5
Document Total:	5
Payment Method	
Cash Account Tot	

CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001865	108356	Closed	7/14/2023	VERT01	VERTILOCITY	0.00	255.00
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002983		31008696		JUNE SOFTWAR	RE 255.00 USD	0.00	255.00
							Document Total:	255.00
							Payment Method Total:	255.00
							Cash Account Total:	255.00
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001868	108357	Closed	7/14/2023	WIMM01	WIMMER JESSICA	0.00	4,003.32
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002984		2046	•	CLINTON COUN		0.00	4,003.32
							Document Total:	4,003.32
							Payment Method Total:	4,003.32
							Cash Account Total:	4,003.32
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001859	108358	Closed	7/14/2023	WINN01	WINN TELECOM	0.00	2,752.35
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
DRADJ	002960		JUNE 2023		LOCAL/LONG DI	S' -298.07 USD	0.00	-298.07
BILL	002985		0410000908 2	2023JULY	LOCAL/LONG DI	S 3,050.42 USD	0.00	3,050.42
							Document Total:	2,752.35
							Payment Method Total:	2,752.35
							Cash Account Total:	2,752.35
CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001869	108359	Closed	7/14/2023	WOOD02	WOOD ADAM	0.00	63.00
Doc. Type	Ref. Number	Branch	Vendor Ref.			Original Amount Currency	Discount Taken	Amount Paid
BILL	002986		BN202201101	182103	REFUND OVERP	PA 63.00 USD	0.00	63.00
							Document Total:	63.00
							Payment Method Total: Cash Account Total:	63.00

CASH AP	USD	CASH ACCOUNT	FOR AP					
Doc. Type	Ref. Number	Payment Ref.	Status	Date	Vendor	Vendor Name	Doc. Balance	Orig. Doc. Amount
CHECK	001860	108360	Closed	7/14/2023	WOOD01	WOOD SARAH	0.00	56.25
Doc. Type	Ref. Number	Branch	Vendor Ref.	Description		Original Amount Currency	Discount Taken	Amount Paid
BILL	002987		06172023		6/12-6/14 CON	ITR/ 56.25 USD	0.00	56.25
							Document Total:	56.25
							Payment Method Total:	56.25
							Cash Account Total:	56.25
						Doc. Type	Count	Amount Paid (USD)
						Check	32	125,129.25
						Prepayment	0	0.00
						Refund	0	0.00
						Void Check	0	0.00
						Company Total:	32	125,129.25

Mid-Michigan District Health Department **Balance Sheet**

As of June 30, 2023

Total Liabilities

Difference

Assets	
Cash & Cash Equivalents	2,744,095.42
Account Receivable	143,970.39
Other Receivables	256,580.60
Prepaid Expenses	6,165.00
VFC Inventory	49,198.09
Total Assets	3,200,009.50
Liabilities	
Employee Deductions	65,664.11
Accounts Payable	26,256.86
Due to Others	197,951.32
VFC Inventory	49,198.09
Trust Funds	17,987.17
Deferred Revenues	0.00
Other Long-term Liabs	198,633.00
38901-FUND BALANCE RESTRICTED DENTAL	95,208.84
39001-FUND BALANCE	163,207.96
39004-FUND BALANCE - TECHNICAL/EQUIP	489,494.46
39005-FUND BALANCE-FACILITY DEV.	137,523.00
39007-FUND BALANCE-SELF INS BONDS	13,949.72
39008-FUND BALANCE-FUTURE RETIREMENT	192,269.58
39009-FUND BALANCE-COMPENSATED LEAVE	549,707.51
39010-FUND BALANCE-UNEMPLOYMENT	55,000.00
39012-FUND BALANCE - TRAINING	35,000.00
39013-FUND BALANCE - BRFS	11,522.00
39014-FUND BALANCE-HEALTH INSURANCE	160,000.00
39015-FUND BALANCE-POTENTIAL CLAIMS	168,289.00
39017-FUND BALANCE CHW	200,000.00
39018-FUND BALANCE OPEB	77,778.00
Net Income / (Loss)	295,368.88

User: MELISSA SELBY

3,200,009.50

0.00

ALL PROGRAMS	BUDGET	CURRENT MONTH	YEAR TO DATE	BUDGET BALANCE	% YTD
REVENUE					
ELPHS	1,147,315.00	79,763.00	908,025.20	239,289.80	79%
MDHHS GRANTS	3,503,257.00	322,941.04	2,760,115.19	743,141.81	79%
MDHHS FEE FOR SERVICE	70,000.00	6,244.74	23,105.80	46,894.20	33%
EGLE GRANTS	85,015.00	89,888.37	138,002.32	-52,987.32	162%
OTHER GRANTS	858,000.00	42,982.04	514,688.41	343,311.59	60%
VFC SUPPLIES	300,000.00	10,305.08	88,293.50	211,706.50	29%
MEDICAID FULL COST	282,000.00	0.00	132,831.00	149,169.00	47%
MEDICAID OUTREACH	53,355.00	24,801.55	27,383.72	25,971.28	51%
MISC INCOME	22,000.00	9,085.68	74,487.48	-52,487.48	339%
CHED ADMINISTRATION	1,000.00	2,932.56	2,932.56	-1,932.56	293%
ORAL HEALTH	0.00	0.00	1,465.00	-1,465.00	
ORAL HEALTH K-ASSESSMENT	0.00	3,050.00	14,649.00	-14,649.00	
CLINICAL VARNISH	10,000.00	146.00	2,208.20	7,791.80	22%
BREASTFEEDING PROGRAM	0.00	-55.00	0.00	0.00	
HEARING	21,000.00	-18.60	9,629.20	11,370.80	46%
VISION	21,000.00	-2.00	8,492.40	12,507.60	40%
FAMILY PLANNING	108,000.00	5,222.68	37,732.89	70,267.11	35%
BCCCP	1,000.00	-234.30	499.90	500.10	50%
BLOOD LEAD	8,100.00	221.91	1,943.47	6,156.53	24%
HIV	1,000.00	0.00	0.00	1,000.00	0%
STD/STI	4,000.00	465.88	2,930.85	1,069.15	73%
IMMUNIZATIONS	130,000.00	8,155.09	112,966.20	17,033.80	87%
COMMUNICABLE DISEASE	2,000.00	0.00	570.00	1,430.00	29%
BODY ART	1,500.00	0.00	0.00	1,500.00	0%
FOOD PROGRAM	315,000.00	3,220.00	304,136.00	10,864.00	97%
WATER PROGRAM	185,000.00	16,819.34	108,137.34	76,862.66	58%
SEWAGE PROGRAM	195,000.00	19,730.00	131,303.00	63,697.00	67%
EH MISC	45,000.00	2,860.00	40,060.08	4,939.92	89%
EH ADMIN	1,000.00	20.82	387.10	612.90	39%
ADMINISTRATION	200.00	0.00	-50.00	250.00	-25%
SPACE	296,599.99	24,193.96	216,379.06	80,220.93	73%
APPROPRIATIONS	1,133,504.01	94,622.92	853,816.53	279,687.48	75%
TOTAL REVENUE	8,800,846.00	767,362.76	6,517,121.40	2,283,724.60	74%

ALL PROGRAMS	BUDGET	CURRENT MONTH	YEAR TO DATE	BUDGET BALANCE	% YTD
EXPENSE					
SALARIES	4,336,979.00	342,379.44	3,083,701.83	1,253,277.17	71%
FICA	331,775.00	25,420.86	226,424.27	105,350.73	68%
HEALTH INSURANCE	913,058.00	75,079.47	674,077.08	238,980.92	74%
DENTAL INSURANCE	57,645.00	3,962.99	37,263.35	20,381.65	65%
RETIREMENT	723,303.00	67,043.09	448,134.85	275,168.15	62%
OTHER BENEFITS	43,786.00	3,587.31	22,882.14	20,903.86	52%
OFFICE SUPPLIES	92,700.00	87.44	89,632.76	3,067.24	97%
COMPUTER SUPPLIES	70,000.00	7,411.68	54,498.07	15,501.93	78%
MEDICAL SUPPLIES	48,800.00	4,663.28	38,645.45	10,154.55	79%
BIOLOGICS	60,500.00	2,309.06	63,406.43	-2,906.43	105%
VFC	300,000.00	10,305.07	88,293.49	211,706.51	29%
OTHER SUPPLIES	0.00	0.00	14,498.48	-14,498.48	
CAPITAL EXPENSE	0.00	99.00	29,151.73	-29,151.73	
SOFTWARE PURCHASES	0.00	0.00	32,075.00	-32,075.00	
CONTRACTUAL	1,056,400.00	70,716.67	617,606.37	438,793.63	58%
LABS	4,200.00	231.20	2,624.20	1,575.80	62%
COMMUNICATIONS	59,400.00	7,335.76	85,046.17	-25,646.17	143%
TRAVEL/TRAINING	171,900.00	14,312.42	120,459.30	51,440.70	70%
MEMBERSHIPS	25,600.00	3,311.69	22,969.23	2,630.77	90%
ADVERTISING	34,100.00	7,962.00	28,271.56	5,828.44	83%
LIABILITY INSURANCE	33,000.00	0.00	46,866.75	-13,866.75	142%
LEASE & MAINTENANCE	111,100.00	72,213.89	145,842.58	-34,742.58	131%
RENT	31,000.00	4,291.67	22,638.00	8,362.00	73%
SPACE	285,600.00	24,193.96	216,379.06	69,220.94	76%
MISC EXPENSE	10,000.00	1,476.58	10,364.37	-364.37	104%
TOTAL EXPENSE	8,800,846.00	748,394.53	6,221,752.52	2,579,093.48	71%
Net Income (Loss)	0.00	18,968.23	295,368.88	-295,368.88	

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

EXPENDITURE CATEGORY	ADMINISTRATIVE SERVICES	INFORMATION TECHNOLOGY	COMMUNITY HEALTH ASSESSMENT	MONTCALM SUBSTANCE USE PREVENTION
Salaries & Wages	578,871	78,648	8,075	174,264
Fringe Benefits	314,369	34,207	2,745	81,814
Capital Expense for Equipment & Facility Develop	-		-	
Contractual (Sub-Contracts)	229,550	123,000	-	-
Supplies & Materials	14,000	10,000	100	2,000
Travel /Training	4,000	3,000	1,000	2,000
Communications	8,000	37,000	100	1,200
Reserves/ Facility Development	-		-	-
Space Costs	35,000	1,000	700	3,000
All Others	140,000	5,000	-	1,000
Total Direct Expenditures	1,323,790	291,855	12,720	265,278
Administrative Overhead	(1,026,196.40)	22,893	2,195	51,945
Information Technology (IT) Overhead	-	(313,748)	686	16,244
EH Administrative Overhead	-		<u>-</u>	
CHED Administrative Overhead	-		-	
Total Expenditures	297,594	1,000	15,601	333,468

REVENUE CATEGORY

Total Revenues:	297,594	1,000	10,700	300,000
Essential Local Public Health Services	-			
MCH Block Grant				
MDHHS -FFS				
MDHHS - CPBC				
MDHHS - CPBC	52,394			
County Reimbursement				
Shared Services - Health Departments	50,000			
MCDC Reimbursement				
Mid-Michigan Health Plan				
Community Support & Other Grants	140,000	-	10,000	297,000
Deferred Revenue	-			
Interest	25,000			
Space	30,000	1,000	700	3,000
Cigarette Tax				
VFC 317				
MA Full Cost Reimbursement				
Federal/State Funding - NON MDHHS				
Fees & Collections - 3rd Party				
Fees 1st & 2nd Party	200			

Local Funds	0	0	4,901	33,468

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

EXPENDITURE CATEGORY	DRUG FREE COMMUNITIES CLINTON	EMERGENCY PREPAREDNESS	EMERGING THREATS/PANDEMIC RESPONSE	PUBLIC HEALTH WORKFORCE DEVT & INFRASTRUCTURE
Salaries & Wages	66,118	74,984	221,804	95,703
Fringe Benefits	20,780	38,271	86,435	39,066
Capital Expense for Equipment & Facility Develop			50,000	-
Contractual (Sub-Contracts)	15,000		920,000	6,000
Supplies & Materials	5,000	1,000	27,000	12,000
Travel /Training	5,000	2,500	5,000	100
Communications	600	1,200	5,000	1,000
Reserves/ Facility Development	-	-	-	-
Space Costs	2,000	4,000	6,000	100
All Others	1,500	1,200	14,000	16,000
Total Direct Expenditures	115,999	123,155	1,335,240	169,969
Administrative Overhead	17,627	22,974	62,526	27,338
Information Technology (IT) Overhead	5,512	7,184	19,553	8,549
EH Administrative Overhead				
CHED Administrative Overhead				
Total Expenditures	139,138	153,313	1,417,319	205,856

REVENUE CATEGORY

Fees 1st & 2nd Party		-		
Fees & Collections - 3rd Party				
Federal/State Funding - NON MDHHS				
MA Full Cost Reimbursement				
VFC 317				
Cigarette Tax				
Space	2,000	4,000	6,000	100
Interest				
Deferred Revenue				
Community Support & Other Grants	125,000			-
Mid-Michigan Health Plan			-	200,000
MCDC Reimbursement				
Shared Services - Health Departments				
County Reimbursement				
MDHHS - CPBC		101,774	477,670	
MDHHS - CPBC		28,443	924,000	
MDHHS -FFS				
MCH Block Grant				
Essential Local Public Health Services				
Total Revenues:	127,000	134,217	1,407,670	200,100

Local Funds	12,138	19,096	9,649	5,756

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

EXPENDITURE CATEGORY	LEAD CM	DRINKING WATER	BODY ART	ENVIRONMENTAL HEALTH ADMINISTRATION
Salaries & Wages	7,037	236,765	3,963	374,346
Fringe Benefits	3,069	110,396	2,127	176,970
Capital Expense for Equipment & Facility Develop				
Contractual (Sub-Contracts)	-	1,000		3,000
Supplies & Materials	1,000	3,000	100	10,000
Travel /Training	1,000	11,000	2,000	1,000
Communications	100	1,500	100	12,000
Reserves/ Facility Development	-	-	<u>-</u>	<u>-</u>
Space Costs	5,000	7,000	2,000	60,000
All Others	-	28,000	-	52,000
Total Direct Expenditures	17,206	398,661	10,290	689,315
Administrative Overhead	2,050	70,421	1,235	111,834
Information Technology (IT) Overhead	641	22,022	386	34,972
EH Administrative Overhead		257,665	4,520	(757,121)
CHED Administrative Overhead				
Total Expenditures	19,897	748,769	16,431	79,000

REVENUE CATEGORY

Total Revenues:	7,000	568,230	3,500	79,000
Essential Local Public Health Services		168,215	-	
MCH Block Grant				
MDHHS-FFS	2,000			
MDHHS - CPBC				
MDHHS - CPBC	-			18,000
County Reimbursement				
Shared Services - Health Departments				
MCDC Reimbursement				
Mid-Michigan Health Plan		168,000		
Community Support & Other Grants				
Deferred Revenue				
Interest				
Space	5,000	7,000	2,000	60,000
Cigarette Tax				
VFC 317				
MA Full Cost Reimbursement				
Federal/State Funding - NON MDHHS		60,015		<u>-</u>
Fees & Collections - 3rd Party				
Fees 1st & 2nd Party	-	165,000	1,500	1,000

Local Funds	12,897	180,539	12,931	0

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

EXPENDITURE CATEGORY	FOOD	ENVIRONMENTAL HEALTH - GENERAL	NUISANCE	SEWAGE
Salaries & Wages	193,082	23,753	14,273	243,244
Fringe Benefits	78,070	9,029	5,685	99,711
Capital Expense for Equipment & Facility Develop				
Contractual (Sub-Contracts)				
Supplies & Materials	7,000	4,000	1,000	3,000
Travel /Training	11,000	4,000	2,000	11,000
Communications	1,500	500	100	1,500
Reserves/ Facility Development	-	-	-	-
Space Costs	6,000	5,000	500	1,000
All Others	500	1,000	-	100
Total Direct Expenditures	297,151	47,282	23,558	359,555
Administrative Overhead	55,003	6,650	4,048	69,568
Information Technology (IT) Overhead	17,200	2,080	1,266	21,755
EH Administrative Overhead	201,250	24,331	14,813	254,543
CHED Administrative Overhead				
Total Expenditures	570,604	80,343	43,685	705,421

REVENUE CATEGORY

Community Support & Other Grants Mid-Michigan Health Plan				
Mid-Michigan Health Plan MCDC Reimbursement				
i				
Shared Services - Health Departments				
County Reimbursement				
MDHHS - CPBC		-		
MDHHS - CPBC				
MDHHS -FFS				
MCH Block Grant				
Essential Local Public Health Services	190,205		-	358,382
Total Revenues:	496,205	78,000	500	584,382

Local Funds	74,399	2,343	43,185	121,039

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

			50,431	80,315
Total Expenditures	80,340	30,549	111,000	84,285
CHED Administrative Overhead	12,471	4,845	(516,719)	12,462
EH Administrative Overhead				
Information Technology (IT) Overhead	3,250	1,263	21,051	3,247
Administrative Overhead	10,392	4,037	67,316	10,384
Total Direct Expenditures	54,228	20,404	539,352	58,191
All Others	-	-	60,500	500
Space Costs	500	100	110,000	4,500
Reserves/ Facility Development	-	-		
Communications	500	100	11,000	500
Travel /Training	1,000	100	5,000	1,000
Supplies & Materials	1,000	200	16,000	500
Contractual (Sub-Contracts)	-	ı	5,000	
Capital Expense for Equipment & Facility Develop				
Fringe Benefits	13,296	5,255	94,351	12,921
Salaries & Wages	37,932	14,648	237,501	38,271
EXPENDITURE CATEGORY	IMMUNIZATION WAIVERS (MCH)	BLOOD LEAD TESTING	COMMUNITY HEALTH AND EDUCATION ADMINISTRATION	COMMUNITY HEALTH AND EDUCATION GENERAL

REVENUE CATEGORY

Fees 1st & 2nd Party		100	500	-
Fees & Collections - 3rd Party		10,000	500	
Federal/State Funding - NON MDHHS				
MA Full Cost Reimbursement				
VFC 317				
Cigarette Tax				
Space	500	100	110,000	4,500
Interest				
Deferred Revenue				
Community Support & Other Grants				
Mid-Michigan Health Plan		-		
MCDC Reimbursement				
Shared Services - Health Departments				
County Reimbursement				
MDHHS - CPBC				35,000
MDHHS - CPBC				
MDHHS -FFS		-		
MCH Block Grant	55,204			
Essential Local Public Health Services				
Total Revenues:	55,704	10,200	111,000	39,500

				i l
Local Funds	<i>24,636</i>	20,349	0	44,785

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

EXPENDITURE CATEGORY	BREAST AND CERVICAL CANCER CONTROL PROGRAM	COMMUNICABLE DISEASE	CHILDREN'S SPECIAL HEALTH CARE SERVICES	COMMUNITY HEALTH WORKERS PROGRAM
Salaries & Wages	10,691	64,660	146,007	41,687
Fringe Benefits	5,186	25,478	66,671	25,075
Capital Expense for Equipment & Facility Develop				
Contractual (Sub-Contracts)	-			
Supplies & Materials	100	4,000	3,000	2,500
Travel /Training	500	1,000	3,000	5,500
Communications	100	3,500	2,000	2,000
Reserves/ Facility Development	-		-	
Space Costs	1,000	4,000	2,000	1,000
All Others	-	3,000	1,300	-
Total Direct Expenditures	17,577	105,638	223,977	77,762
Administrative Overhead	3,221	18,284	43,141	13,543
Information Technology (IT) Overhead	1,007	5,718	13,491	4,235
EH Administrative Overhead				
CHED Administrative Overhead	3,865	21,943	51,773	16,252
Total Expenditures	25,669	151,583	332,383	111,791

REVENUE CATEGORY

Total Revenues:	2,000	150,609	261,391	111,000
Essential Local Public Health Services		144,039		
MCH Block Grant				
MDHHS -FFS		570	55,000	
MDHHS - CPBC			2,662	
MDHHS - CPBC			116,729	
County Reimbursement				
Shared Services - Health Departments				
MCDC Reimbursement				
Mid-Michigan Health Plan				110,000
Community Support & Other Grants		-		
Deferred Revenue				
Interest				
Space	1,000	4,000	2,000	1,000
Cigarette Tax			-	
VFC 317				
MA Full Cost Reimbursement			85,000	
Federal/State Funding - NON MDHHS				
Fees & Collections - 3rd Party	1,000	-	-	-
Fees 1st & 2nd Party	-	2,000	-	-

Local Funds	23,669	974	70,992	791

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

EXPENDITURE CATEGORY	FAMILY PLANNING	HEARING	HIV	IMMUNIZATION
Salaries & Wages	145,134	52,821	7,281	132,702
Fringe Benefits	66,839	11,351	2,432	55,863
Capital Expense for Equipment & Facility Develop				
Contractual (Sub-Contracts)				
Supplies & Materials	37,000	500	6,000	355,000
Travel /Training	4,000	6,000	1,000	4,000
Communications	1,000	800	100	1,500
Reserves/ Facility Development		ı	ı	ı
Space Costs	5,000	2,000	2,500	2,500
All Others	3,000	800	-	2,000
Total Direct Expenditures	261,973	74,272	19,313	553,565
Administrative Overhead	42,999	13,017	1,970	38,250
Information Technology (IT) Overhead	13,446	4,071	616	11,961
EH Administrative Overhead				
CHED Administrative Overhead	51,601	15,622	2,365	45,903
Total Expenditures	370,019	106,981	24,264	649,680

REVENUE CATEGORY

Fees 1st & 2nd Party	15,000	1,000	1,000	25,000
Fees & Collections - 3rd Party	65,000	20,000	-	175,000
Federal/State Funding - NON MDHHS				
MA Full Cost Reimbursement	65,000	1,000		45,000
VFC 317				300,000
Cigarette Tax				
Space	5,000	2,000	2,500	2,500
Interest				
Deferred Revenue				
Community Support & Other Grants				
Mid-Michigan Health Plan		-		
MCDC Reimbursement				
Shared Services - Health Departments				
County Reimbursement				
MDHHS - CPBC	174,023		20,000	26,833
MDHHS - CPBC				
MDHHS -FFS				-
MCH Block Grant				
Essential Local Public Health Services		49,235		73,000
Total Revenues:	324,023	73,235	23,500	647,333

Local Funds	45,996	33,746	764	2,347

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

EXPENDITURE CATEGORY	IMMUNIZATION ACTION PROGRAM	MEDICAID OUTREACH	SEXUALLY TRANSMITTED DISEASE TESTING AND PREVENTION	VISION
Salaries & Wages	97,114	76,335	64,414	52,821
Fringe Benefits	43,741	33,177	25,900	11,351
Capital Expense for Equipment & Facility Develop				
Contractual (Sub-Contracts)				
Supplies & Materials	1,000	300	1,000	500
Travel /Training	5,000	3,000	2,000	5,000
Communications	1,500	100	500	800
Reserves/ Facility Development	-	-	-	-
Space Costs	1,000	2,000	5,000	800
All Others	500	-	500	800
Total Direct Expenditures	149,856	114,912	99,314	72,072
Administrative Overhead	28,573	22,215	18,320	13,017
Information Technology (IT) Overhead	8,935	6,947	5,729	4,071
EH Administrative Overhead				
CHED Administrative Overhead	34,289	26,659	21,986	15,622
Total Expenditures	221,652	170,733	145,349	104,781

REVENUE CATEGORY

Total Revenues:	176,075	87,366	126,000	72,035
Essential Local Public Health Services			115,000	49,235
MCH Block Grant				
MDHHS -FFS	15,000			
MDHHS - CPBC				
MDHHS - CPBC	85,075			
County Reimbursement				
Shared Services - Health Departments				
MCDC Reimbursement				
Mid-Michigan Health Plan				
Community Support & Other Grants				
Deferred Revenue				
Interest				
Space	1,000	2,000	5,000	800
Cigarette Tax				
VFC 317				
MA Full Cost Reimbursement	75,000	85,366		1,000
Federal/State Funding - NON MDHHS				
Fees & Collections - 3rd Party	-		5,000	20,000
Fees 1st & 2nd Party			1,000	1,000

Local Funds	45,577	83,366	19,349	32,746

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

EXPENDITURE CATEGORY	WIC	WIC PEER COUNSELING	ORAL HEALTH KINDEGARTEN PROGRAM	FLUORIDE VARNISH- CLINIC
Salaries & Wages	392,356	68,170	39,238	22,350
Fringe Benefits	154,566	25,293	21,142	12,457
Capital Expense for Equipment & Facility Develop				
Contractual (Sub-Contracts)				
Supplies & Materials	3,000	1,500	1,500	1,000
Travel /Training	2,000	500	4,000	2,000
Communications	3,500	2,000	300	300
Reserves/ Facility Development	-	-		
Space Costs	4,800	2,000	1,000	1,000
All Others	2,100	1,000	100	100
Total Direct Expenditures	562,322	100,463	67,280	39,207
Administrative Overhead	110,943	18,959	12,248	7,061
Information Technology (IT) Overhead	34,693	5,929	3,830	2,208
EH Administrative Overhead				
CHED Administrative Overhead	133,139	22,752	14,699	8,473
Total Expenditures	841,097	148,102	98,057	56,949

REVENUE CATEGORY \$1,687,000

Total Revenues:	709,897	127,721	97,537	56,000
Essential Local Public Health Services				
MCH Block Grant				30,000
MDHHS -FFS				
MDHHS - CPBC				
MDHHS - CPBC	705,097	125,721	61,537	
County Reimbursement				
Shared Services - Health Departments				
MCDC Reimbursement				
Mid-Michigan Health Plan				
Community Support & Other Grants			25,000	15,000
Deferred Revenue				
Interest				
Space	4,800	2,000	1,000	1,000
Cigarette Tax				
VFC 317				
MA Full Cost Reimbursement	-	-		
Federal/State Funding - NON MDHHS				
Fees & Collections - 3rd Party	-		10,000	10,000
Fees 1st & 2nd Party	-			

Local Funds	131,200	20,381	520	949

FISCAL YEAR 23-24 BUDGET 10/01/23-09/30/24

·	10/01/23-09/30/24	DGLI	
EXPENDITURE CATEGORY	TOTAL	PRIOR YEAR (22-23)	Difference
Salaries & Wages	4,137,063	4,336,972	(199,909)
Fringe Benefits	1,815,089	2,069,574	(254,485)
Capital Expense for Equipment & Facility Develop	50,000	-	<u>-</u>
Contractual (Sub-Contracts)	1,302,550	1,246,370	56,180
Supplies & Materials	535,800	642,000	(106,200)
Travel /Training	121,200	171,900	(50,700)
Communications	103,500	59,400	44,100
Reserves/ Facility Development	-	-	-
Space Costs	291,000	316,600	(25,600)
All Others	336,500	238,000	98,500
Total Direct Expenditures	8,692,702	9,080,816	(388,114)
Administrative Overhead	0	(0)	-
Information Technology (IT) Overhead	0	(0)	<u>-</u>
EH Administrative Overhead	-	-	<u>-</u>
CHED Administrative Overhead	(0)	0	-
Total Expenditures	8,692,702	9,080,816	(388,114)
REVENUE CATEGORY	\$8,249,648		
Fees 1st & 2nd Party	779,300	794,300	(15,000)
Fees & Collections - 3rd Party	316,500	257,500	59,000
Federal/State Funding - NON MDHHS	93,015	85,015	8,000
MA Full Cost Reimbursement	357,366	335,354	22,012
VFC 317	300,000	300,000	-
Cigarette Tax	-	-	-
Space	286,000	296,600	(10,600)
Interest	25,000	20,000	5,000
Deferred Revenue		-	,
Community Support & Other Grants	612,000	788,000	(176,000)
Mid-Michigan Health Plan	478,000	20,000	458,000
MCDC Reimbursement	-	-	-
Shared Services - Health Departments	50,000	50,000	
County Reimbursement			-
MDHHS - CPBC	1,999,853	2,847,203	(847,350)
			,

Local Funds (Appropriations)

Essential Local Public Health Services

Total Revenues:

MDHHS - CPBC MDHHS -FFS

MCH Block Grant

Local Funds	1,135,478	1,135,478	(0)

955,105

72,570

85,204

1,147,311

7,557,224

848,850

70,000

85,204

1,147,315

5,997,857

106,255

1,559,367

2,570

(4)



BOARD OF HEALTH:

CLINTON OFFICE

1307 E. Townsend Rd. Saint Johns, MI 48879-9036 (989) 224-2195

Bruce DeLong

David Pohl

GRATIOT OFFICE

151 Commerce Dr. Ithaca, MI 48847-1627 (989) 875-3681

George Bailey

Timothy Gay

MONTCALM OFFICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

Phil Kohn

Adam Petersen

Mid-Michigan District Health Department (MMDHD)

FY 23/24 Proposed Budget

Budget Overview and Comparative Summary

A. MMDHD Budget Process

Under the Michigan Public Health Code (Section 2415 of P.A. 368 of 1978) and the Agency's Intergovernmental Agreement, the MMDHD is operated by and serves Clinton, Gratiot and Montcalm Counties. This occurs via a **District Board of Health** comprised of two members each from the three County Boards of Commissioners, with current membership including:

Bruce DeLong (Clinton)

George Bailey (Gratiot)

Phil Kohn (Montcalm)

David Pohl (Clinton)

Timothy Gay (Gratiot)

Adam Petersen (Montcalm)

The Michigan Public Health Code (Section 2417) and the Agency's Intergovernmental Agreement require the District Board of Health to approve all expenditures of the local health department and to use a mutually agreeable funding formula for allocating costs among the participating counties in approving each fiscal year's budget. Once reviewed and approved by the District Board of Health, the proposed budget allocations are forwarded to the individual County Boards of Commissioners for final approval to set each county's public health general fund appropriation.

B. Funding Allocation Principles

- Allocations among the counties need to avoid large swings/shifts in local funding requests from year-to-year and need to be "equitable" related to services received.
- Agency staffing and programs currently meet State Accreditation minimum standards and need a fixed base of funding support to maintain them.
- The Intergovernmental Agreement includes a specific mechanism for determining how the
 appropriation dollars are allocated among the three counties. The contribution request is allocated
 with a base amount, and any increments pro-rata among the counties based on average percentages
 of actual staff time worked by county in each program service area over the most recent five years,
 applied to the proposed annual budget. (See the attached Local Appropriations Policy approved by the
 BOH.)

C. FY 23/24 Budget Information and Assumptions

- The 23/24 Budget assumes that state/federal funding will remain at level funding for most programs. There remains funding streams for emerging threats and the pandemic response in the 23/24 fiscal year although the amount has decreased over the previous fiscal year. The amounts for these grants have been released by the State. The program grants as well as fees collected will need to be monitored closely in the upcoming fiscal year and adjustments will be made if necessary.
- The Michigan Care Improvement Registry Program (MCIR) has been removed from the budget as the State of Michigan has moved this funding to the Michigan Public Health Institute (MPHI).

- The communication line item has been increased to cover the increased quantity of cell phone users.
- This budget has a reduction of 5.4 Full Time Equivalents (FTE) which include the two MCIR staff
 members, two Information Technology staff as we have contracted for these services, one Data
 Specialist, and other slight changes for the remaining staffing.
- There is dedicated funding for the agency retirement plan, as proposed and approved by the Board of Health, to increase the percentage level of funding.

D. FY 23/24 Budget Development Summary

As in past years, efforts to reduce expenses in areas where possible were made. The budget will need to be monitored carefully in the upcoming fiscal year. There have been some increases in operations such as health insurance increases, retirement costs, wage increases, communications, etc. but we have tried to be diligent in attempting to keep costs down and increase revenue streams such as through grant funding and billing commercial insurances, etc. MMDHD is not requesting an overall appropriation increase for the FY 23/24 budget.

E. Board of Health and County Requested Allocations

FY 23/24 County Allocation Request	<u>Clinton</u>	<u>Gratiot</u>	<u>Montcalm</u>
Prior Year (FY 22/23) Appropriation Amount	\$400,645	\$292,672	\$442,161
Changes Based on Service Trends (IGA)	<u>\$2,349</u>	<u>\$8,855</u>	\$(11,204)
FY 23/24 Totals = \$1,135,478	\$402,994	\$301,527	\$430,957

ENVIRONMENTAL HEALTH DIVISION FEE SCHEDULE Fiscal Year 23-24 Proposal

	Approved 22/23	Proposed 23/24
Sewage Program	Fees	
Vacant Land Evaluation	195.00	200.00
New Sewage Disposal Permit (Vacant Land Evaluation Required)	225.00	230.00
Alternate System Review/Gravity Mound Inspection	95.00	95.00
Permit - New	420.00	430.00
Replacement Sewage System	255.00	260.00
Reissuance of Alternative Permit	95.00	95.00
Permit Renewal Prior to Expiration	55.00	55.00
Revisit Vacant Land/Relocation	155.00	160.00
Re-inspection fee for septic systems	105.00	110.00
Non-Residential Sewa	ige Fees	
0 - 1,000 gpd - New	525.00	535.00
>1,000 gpd<10,000 gpd - New	685.00	700.00
>10,000 gpd<20,000 gpd - New	880.00	900.00
0 - 1,000 gpd - Repair	525.00	535.00
>1,000 gpd<10,000 gpd - Repair	685.00	700.00
>10,000 gpd<10,000 gpd - Repair	880.00	900.00
Septic Waste Hauler F	Program	
New Evaluation - per 20 acres	235.00	240.00
Annual Site Inspection Fee	235.00	240.00
Truck Inspection Fee	90.00	92.00
Water Supply Prog	ıram	
Water Supply Permit - New	255.00	260.00
Water Supply Permit - Replacement	255.00	260.00
Type II - New	320.00	325.00
Type II - Repair	320.00	325.00
Type III - New	365.00	375.00
Type III - Repair	365.00	375.00
Irrigation Well	365.00	375.00
Sewage/Well Evalua	ations	
Sewage Evaluation	200.00	205.00
Water Evaluation	215.00	220.00
Sewage Evaluation - Combined	145.00	150.00
Water Evaluation - Combined	190.00	195.00
Lead Water Sample	0.00	0.00
Existing Site Septic/Well Evaluation	120.00	125.00

ENVIRONMENTAL HEALTH DIVISION FEE SCHEDULE Fiscal Year 23-24 Proposal

	Approved 22/23	Proposed 23/24
D.H.S. Facility Inspe	ction	
Partial Inspection Request	215.00	220.00
Full Inspection Request	310.00	315.00
Plan Review - Full Facility	315.00	320.00
Campgrounds		
Inspection Fee Annual Campgrounds	110.00	115.00
Public Swimming P	ools	
Inspection Fee - MMDHD (Per Pool)	110.00	115.00
Plats/Subdivisior	าร	
On-Site Sewage & Private Water System Application Fee	680.00	695.00
Per Lot Fee	40.00	40.00
Sanitary Sewer & Private Water System Application Fee	550.00	560.00
Per Lot Fee	25.00	25.00
On-Site Sewage & Public Water System Application Fee	550.00	560.00
Per Lot Fee	40.00	40.00
Food Services Prog	gram	
Fixed Foods: Type I	200.00	205.00
Fixed Foods: Type II	210.00	215.00
Fixed Foods: Type III	580.00	590.00
Fixed Foods: Type IV	605.00	615.00
Fixed Foods: Type V	635.00	650.00
Mobile Food	375.00	380.00
Site Consultation Fee	200.00	205.00
Late License Fee 0-30 days	140.00	145.00
Late License Fee 31-60 days	275.00	280.00
Late License Fee 61-90 days	415.00	425.00
Late License Fee 91 & over days	550.00	560.00
Enforcement Increased Inspection Frequency	240.00	245.00
Re-Inspection After Hearing	240.00	245.00
Enforcement Informal Hearing Fee	340.00	345.00
Enforcement Formal Hearing Fee	570.00	580.00
Temporary Food - Profit	90.00	90.00
Temporary Food - Non-Profit	90.00	90.00
Temporary Food - Late License Fee	35.00	35.00
Food Establishment - Full Review/Major Remodel	625.00	635.00
Food Establishment - Partial Review/Minor Remodel	310.00	315.00
Advanced Food Training	130.00	130.00
Food Handler Class	20.00	20.00
Re-Certification Class	130.00	130.00

ENVIRONMENTAL HEALTH DIVISION FEE SCHEDULE Fiscal Year 23-24 Proposal

	Approved 22/23	Proposed 23/24
Body Art		
Routine Inspection	290.00	295.00
Follow-up Inspection	175.00	180.00
Plan Review	310.00	315.00
BBP Certification	25.00	25.00
Temporary Body Art License	230.00	235.00
Other		
Septic Installers Registration 2 Years	100.00	100.00
Septic Installers Registration - Test/Late Fees	70.00	70.00
Appeal to Board of Health	190.00	195.00
Disinterment/Reinterment	25.00	25.00
Radon Test Kit - Alpha	25.00	25.00
Mercury Spill Kit	20.00	20.00
AOI Inspection Fee	115.00	115.00
Type II Water Sampling	65.00	65.00
E.H. Service Late Fee - after 60 days; applied each month thereafter	55.00	55.00
E.H. Enforcement Fee	210.00	215.00
Water Sample - Courier Service	5.00	5.00
F.O.I.A - (\$ based on time and supplies used)		

^{*}Campgrounds and pool licensing fees are determined and collected by the State of Michigan not included above.

^{**}Food licensing has a surcharge determined by the State of Michigan, collected by MMDHD which is not included above.

^{***}STFU License and Inspection Fees are determined by the State of Michigan collected by MMDHD. A portion of the set fee is sent to the state.

COMMUNITY HEALTH & EDUCATION DIVISION FEE SCHEDULE

Proposed - FY 23-24

Serial Number	CPT Code	CPTTitle	22/23 Approved Fees	23/24 Proposed Fees
		Administration COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL		
1	0031A	first dose	37.85	37.85
2	90473	Administration of 1 nasal or oral vaccine	20	20
3	90471	Administration of 1 vaccine	20	20
4	G0010	Administration of hepatitis b vaccine	20	20
5	G0008	Administration of influenza virus vaccine	20	20
6	90474	Administration of nasal or oral vaccine	20	20
7	G0009	Administration of pneumococcal vaccine	20	20
8	90472	Administration of vaccine	20	20
9	S0612	Annual gynecological examination, established patient	150	150
		Automated or semi-automated visual function screening of both		
10	99172	eyes	10	10
	Q0144	Azithromycin dihydrate, oral, capsules/powder, 1 gram	0	(
12	83986	Body fluid pH level	3	3
	46900	Chemical destruction of anal growths	365	365
	54050	Chemical destruction of growths of penis	200	200
	S4993	Contraceptive pills for birth control	20	20
	A4267	Contraceptive supply, condom, male, each	0.3	0.3
	J7303	Contraceptive supply, hormone containing vaginal ring, each	30	30
	A4269	Contraceptive supply, spermicide (e.g., foam, gel), each	10	10
	99195	Court Ordered Testing	170	170
	56515	Destruction of extensive growths of external female genitals	335	335
	56501	Destruction of external female genital growths	155	155
	54065	Destruction of external female general growths Destruction of multiple penile growths	325	325
	87273	Detection test for herpes simplex virus type 2	15	15
	87800	· · · · · · · · · · · · · · · · · · · ·	0	C
		Detection test for multiple organisms		16
	87808	Detection test for Trichomonas vaginal (genital parasite)	16	
26	87661	Detection test for Trichomonas vaginalis (genital parasite)	11.5	11.5
27	00040	Established patient office or other outpatient visit, typically 10	60	60
27	99212	minutes	60	60
20	00040	Established patient office or other outpatient visit, typically 15	405	405
28	99213	minutes	105	105
		Established patient office or other outpatient visit, typically 5		
29	99211	minutes	28	28
		Established patient office or other outpatient, visit typically 25		
30	99214	minutes	150	150
		Established patient periodic preventive medicine examination age		
31	99395	18-39 years	170	170
		Established patient periodic preventive medicine examination age		
32	99396	40-64 years	185	185
		Established patient periodic preventive medicine examination, age		
33	99394	12 through 17 years	165	165
		Established patient periodic preventive medicine examination, age		
34	99393	5 through 11 years	140	140
		Established patient periodic preventive medicine examination, age		
35	99397	65 years and older	195	195
		Etonogestrel (contraceptive) implant system, including implant and		
	J7307	supplies	850	850
37	V5008	Hearing screening	10	10
		Immunization administration by intramuscular injection of severe		
		acute respiratory syndrome coronavirus 2 (SARS-CoV-2)		
		(coronavirus disease [COVID-19]) vaccine, DNA, spike protein,		
		adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral		
38	0034A	particles/0.5 mL dosage; booster dose	37.85	37.85

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent sellented for the protein preservative free, 3 mc	37.85 37.85 37.85
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85	37.85 37.85
spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85 37.85
37.85 Secondary State Sec	37.85 37.85
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85 37.85
acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
40 0151A reconstituted, tris-sucrose formulation; single dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85	37.85
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
41 0173A reconstituted, tris-sucrose formulation, third dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
42 0171A reconstituted, tris-sucrose formulation; first dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.63
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
43 0172A reconstituted, tris-sucrose formulation; second dose 37.85 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	37.85
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-	
44 0124A sucrose formulation, booster dose 37.85	37.85
Immunization administration by intramuscular injection of severe	
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent	
spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-	
45 0121A sucrose formulation; single dose 37.85	37.85
Immunization administration by intramuscular injection of severe	
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike	
protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster	
46 0164A dose 37.85	37.85
Immunization administration by intramuscular injection of severe	
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike	
protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first	
47 0141A	37.85
Immunization administration by intramuscular injection of severe	37.83
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike	
protein, bivalent, preservative free, 25 mcg/0.25 mL dosage;	
48 0142A second dose 37.85	37.85
Immunization administration by intramuscular injection of severe	
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike	
protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster	
49 0134A dose 37.85	37.85
Immunization administration by intramuscular injection of severe	
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	
(coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein,	
50 0144A bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose 37.85	37.85

		Immunization administration by intramuscular injection of severe		
		acute respiratory syndrome coronavirus 2 (SARS-CoV-2)		
		(coronavirus disease [COVID-19]) vaccine, recombinant spike		
		protein nanoparticle, saponin-based adjuvant, preservative free, 5		
51	0041A	mcg/0.5mL dosage; first dose	37.85	37.85
		Immunization administration by intramuscular injection of severe		
		acute respiratory syndrome coronavirus 2 (SARS-CoV-2)		
		(coronavirus disease [COVID-19]) vaccine, recombinant spike		
		protein nanoparticle, saponin-based adjuvant, preservative free, 5		
F 2	00424		37.85	37.85
52	0042A	mcg/0.5mL dosage; second dose	37.63	37.83
	00000	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative		,
53	90686	free, 0.5 mL dosage, for intramuscular use	0	(
54	99385	Initial new patient preventive medicine evaluation age 18-39 years	185	185
55	99386	Initial new patient preventive medicine evaluation age 40-64 years	215	215
		Initial new patient preventive medicine evaluation, age 12 through		
56	99384	17 years	190	190
		Initial new patient preventive medicine evaluation, age 5 through		
57	99383	11 years	160	160
- 57	33303	Initial new patient preventive medicine evaluation, age 65 years	100	100
ΕO	00207	and older	225	225
36	99387		225	225
		Initial preventive physical examination; face-to-face visit, services		
		limited to new beneficiary during the first 12 months of medicare		
59	G0402	enrollment	305	305
		Injection beneath the skin or into muscle for therapy, diagnosis, or		
60	96372	prevention	35	35
61	J0696	Injection, ceftriaxone sodium, per 250 mg	0	(
62	J1050	Injection, medroxyprogesterone acetate, 1 mg	0.48	0.48
63	11981	Insertion of drug implant, non-biodegradable	200	200
	36415	Insertion of needle into vein for collection of blood sample	30	30
	J7300	Intrauterine copper contraceptive	485	485
	S9443	Lactation classes, non-physician provider, per session	55	55
	83655	Lead level	15	15
07	03033		13	13
	.====	Levonorgestrel-releasing intrauterine contraceptive system, 52 mg,		
68	J7298	5 year duration	670	670
		Meningococcal conjugate vaccine, serogroups A, C, W, Y,		
69	90619	quadrivalent, tetanus toxoid carrier (MenACWY-TT), for IM use	153	153
		Meningococcal recombinant protein and outer membrane vesicle		
		vaccine, serogroup B (MenB), 2 dose schedule, for intramuscular		
70	90620	use	196	196
	99201	New patient office or other outpatient visit, typically 10 minutes	75	75
71		New patient office or other outpatient visit, typically 20 minutes	_	115
	99202	incw patient office of other outpatient visit, typically 20 minutes	115	
72	99202 99203			
72 73	99203	New patient office or other outpatient visit, typically 30 minutes	160	160
72 73 74	99203 0044A	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster	160 37.85	160 37.85
72 73 74 75	99203 0044A D0191	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient	160 37.85 25	160 37.8! 2!
72 73 74 75 76	99203 0044A D0191 D0190	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient	160 37.85 25 15	160 37.89 29
72 73 74 75 76 77	99203 0044A D0191 D0190 0174A	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster	160 37.85 25 15 37.85	160 37.89 29 19 37.89
72 73 74 75 76 77	99203 0044A D0191 D0190	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention	160 37.85 25 15	160 37.89 29 19 37.89
72 73 74 75 76 77 78	99203 0044A D0191 D0190 0174A 58300	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for	160 37.85 25 15 37.85 100	160 37.85 25 15 37.85 100
72 73 74 75 76 77 78	99203 0044A D0191 D0190 0174A 58300	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use	160 37.85 25 15 37.85 100	166 37.89 29 19 37.89 100
72 73 74 75 76 77 78 79	99203 0044A D0191 D0190 0174A 58300 90677 90670	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle	160 37.85 25 15 37.85 100 0	166 37.89 29 11 37.89 100 (
72 73 74 75 76 77 78 79 80	99203 0044A D0191 D0190 0174A 58300 90677 90670 J8499	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle Prescription drug, oral, non chemotherapeutic, nos	160 37.85 25 15 37.85 100 0 297	166 37.89 29 19 37.89 100 (29)
72 73 74 75 76 77 78 79 80 81 82	99203 0044A D0191 D0190 0174A 58300 90677 90670 J8499 99401	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle Prescription drug, oral, non chemotherapeutic, nos Preventive medicine counseling, approximately 15 minutes	160 37.85 25 15 37.85 100 0 297 0	166 37.89 19 37.89 100 (29)
72 73 74 75 76 77 78 79 80 81 82	99203 0044A D0191 D0190 0174A 58300 90677 90670 J8499	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle Prescription drug, oral, non chemotherapeutic, nos	160 37.85 25 15 37.85 100 0 297	166 37.89 19 37.89 100 (29)
72 73 74 75 76 77 78 79 80 81 82 83	99203 0044A D0191 D0190 0174A 58300 90677 90670 J8499 99401	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle Prescription drug, oral, non chemotherapeutic, nos Preventive medicine counseling, approximately 15 minutes	160 37.85 25 15 37.85 100 0 297 0	166 37.85 25 11 37.85 100 (297 (55
72 73 74 75 76 77 78 79 80 81 82 83 84	99203 0044A D0191 D0190 0174A 58300 90677 90670 J8499 99401 99402 99403	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle Prescription drug, oral, non chemotherapeutic, nos Preventive medicine counseling, approximately 15 minutes Preventive medicine counseling, approximately 30 minutes	160 37.85 25 15 37.85 100 0 297 0 55	160 37.85 25 37.85 100 (297 (55 135
72 73 74 75 76 77 78 80 81 82 83 84	99203 0044A D0191 D0190 0174A 58300 90677 90670 J8499 99401 99402 99403 99404	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle Prescription drug, oral, non chemotherapeutic, nos Preventive medicine counseling, approximately 15 minutes Preventive medicine counseling, approximately 30 minutes Preventive medicine counseling, approximately 45 minutes Preventive medicine counseling, approximately 60 minutes	160 37.85 25 15 37.85 100 0 297 0 55 135 150	160 37.85 25 15 37.85 100 (297 (297 (55 135 150
72 73 74 75 76 77 78 80 81 82 83 84 85	99203 0044A D0191 D0190 0174A 58300 90677 90670 J8499 99401 99402 99403 99404 36416	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle Prescription drug, oral, non chemotherapeutic, nos Preventive medicine counseling, approximately 15 minutes Preventive medicine counseling, approximately 30 minutes Preventive medicine counseling, approximately 45 minutes Preventive medicine counseling, approximately 60 minutes Preventive of skin for collection of blood sample	160 37.85 25 15 37.85 100 0 297 0 55 135 150 171	160 37.85 25 37.85 100 (297 (35 135 150
72 73 74 75 76 77 78 79 80 81 82 83 84 85	99203 0044A D0191 D0190 0174A 58300 90677 90670 J8499 99401 99402 99403 99404	New patient office or other outpatient visit, typically 30 minutes Novavax Covid-19 Vaccine, Adjuvanted Administration - Booster Oral Assessment of Patient Oral Screening of Patient Pfizer-BioNTech Covid-19 Bivalent Booster Placement of intra-uterine device (IUD) for pregnancy prevention Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal vaccine for injection into muscle Prescription drug, oral, non chemotherapeutic, nos Preventive medicine counseling, approximately 15 minutes Preventive medicine counseling, approximately 30 minutes Preventive medicine counseling, approximately 45 minutes Preventive medicine counseling, approximately 60 minutes	160 37.85 25 15 37.85 100 0 297 0 55 135 150	160 37.85 25 37.85 100 (297 (55 135 150

Removal of growth (O.6 to 1.0 centimeters) of the scalp, neck, 89 11421 hands, feet, or genitals 150 90 58301 Removal of intra-uterine device (IUD) for pregnancy prevention 135 91 11983 Removal with reinsertion of drug delivery implant into tissue 321 Screening papanicolaou smear; obtaining, preparing and 160	90 91	58301	hands, feet, or genitals		150
90 58301 Removal of intra-uterine device (IUD) for pregnancy prevention 91 11983 Removal with reinsertion of drug delivery implant into tissue 92 (20091 Screening papanicolaou smear; obtaining, preparing and 92 (20091 conveyance of cervical or vaginal smear to laboratory 15 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.3 mL dosage, tris- spike protein, preservative free, 30 mcg/0.3 mL dosage, tris- spike protein, preservative free, 30 mcg/0.3 mL dosage, tris- spike protein, preservative free, 30 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 55 mcg/0.55 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 0.5 mL dosage, suspension, for spital protein, bivalent, preservative free, 0.5 m	90 91	58301			150
91 11983 Removal with reinsertion of drug delivery implant into tissue 321 Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory 15 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free,	91			125	125
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory 15 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mt dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mt dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mt dosage, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 30 mcg/0.3 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 55 mcg/0.5 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 55 mcg/0.5 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, precombinant spike protein, bivalent, preser					135
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particle/0.5mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mcname, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, preservative free, 5 mcg/0.5 mL dosage, for intramuscul	92	11963		321	321
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, p.NA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.55 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.55 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, recombinant spike protein, bivalent, preservative free, 50 mcg/0.55 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.55 mL dosage, suspension, for subcutaneous injection 5 Small	92	00001		15	15
(coronavirus disease (COVID-19)) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5.1010 viral adenovirus type 26 (Ad26) vector, preservative free, 5.1010 viral particles/0.5mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for 10 mcg/0.2 mL dosage, suspension, for 10 mcg/0.2 mL dosage, for 10 mcg/0.2 mL dosage, for 10 mcg/0.2 mL dosage, suspension, for 10 mcg/0.2 mL dosage, for 10 mcg/0.2 mL dosage, suspension, for 10 mcg/0.2 mL dosage, 10 mcg/0.2 mL dosage, 1		Q0091		15	15
adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/D.5mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mt dosage, diluent spike protein, preservative free, 10 mcg/0.2 mt dosage, diluent spike protein, preservative free, 10 mcg/0.2 mt dosage, diluent spike protein, preservative free, 3 mcg/0.2 mt dosage, diluent spike protein, preservative free, 3 mcg/0.2 mt dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mt dosage, tris-spike protein, preservative free, 30 mcg/0.3 mt dosage, tris-spike protein, preservative free, 30 mcg/0.3 mt dosage, for spike protein, bivalent, preservative free, 25 mcg/0.25 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mt dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mt dosage, for intramuscular use 0 Severe a					
93 91303 particles/0.5mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent 95 91317 reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris- spike protein, preservative free, 30 mcg/0.3 mL dosage, tris- sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use O Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use O Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, recombinant spike protein nanopartice, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use O Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, recombinant spike protein nanopartice, saponin-based adjuvant, preservative free, 5 mcg/0.					
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein, bivalent, preservative free, 5 mg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein, bivalent, preservative free, 5 mg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mg/0.5 mL d	03	01202			0
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mt dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mt dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mt dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mt dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mt dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mt dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein, bivalent, preservative free, 50 mcg/0.5 mt dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein, bivalent, preservative free, 50 mcg/0.5 mt dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mt dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mt dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenu	93	91303		0	0
spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mcg/0.5 mL dosage, for 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservativ					
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-spike protein, preservative free, 25 mcg/0.25 mL dosage, for (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free,					
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccini	0/	01215		0	0
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use 0 Sound monkeyoox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL d		71313		<u> </u>	
spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris- 96 91312 sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for 97 91314 intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for 98 91313 intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for 99 91304 mcg/0.5mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 101 90611 subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 102 90611 subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 102 90611 subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 102 90611 subcutaneous injection 100 100 100 100 100 100 100 100 100 10					
95 91317 reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 96 91312 sucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use 0 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 101 90611 subcutaneous injection 102 90611 subcutaneous injection 103 87210 Smear for infectious agents 104 D1206 Topical fluoride varnish; Dental Varnish 105 81025 Urine pregnancy test 106 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 102 90611 subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 105 Urine pregnancy test Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	Q	01317		0	0
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 101 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish; Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	3.	91317		0	0
spike protein, preservative free, 30 mcg/0.3 mL dosage, tris- sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use Samallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection O Topical fluoride varnish;Dental Varnish Topical fluoride varnish;Dental Varnish Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
96 91312 sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use O Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use O Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use O Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection O Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection O 102 90611 subcutaneous injection O 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish; Dental Varnish 30 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 101 90611 subcutaneous injection 0 102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	04	01212			0
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 101 90611 subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 101 90611 Subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 102 90611 Subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 30 102 90611 Subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	90	91312	•	U	
protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 102 90611 subcutaneous injection 103 87210 Smear for infectious agents 104 D1206 Topical fluoride varnish; Dental Varnish 105 81025 Urine pregnancy test Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
97 91314 intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 102 90611 subcutaneous injection 0 subcutaneous injection 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish; Dental Varnish 105 81025 Urine pregnancy test Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 102 90611 subcutaneous injection 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	0-	7 01214			0
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 102 90611 subcutaneous injection 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	91	91314		U	0
protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
98 91313 intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish; Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	0.9	01212			0
(coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 0 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 101 90611 subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	90	91313		U	
protein nanoparticle, saponin-based adjuvant, preservative free, 5 99 91304 mcg/0.5mL dosage, for intramuscular use 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 101 90611 subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 102 90611 subcutaneous injection 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
99 91304 mcg/0.5mL dosage, for intramuscular use 100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 101 90611 subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for 102 90611 subcutaneous injection 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
100 86580 Skin test for tuberculosis 20 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	Q	01204		0	
Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for		1			25
nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 Urine pregnancy test Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	100	80380		20	
101 90611 subcutaneous injection 0 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	101	90611		0	0
nonreplicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	10.	30011	-	U	
102 90611 subcutaneous injection 0 103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for					
103 87210 Smear for infectious agents 13 104 D1206 Topical fluoride varnish; Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for	101	00611		0	0
104 D1206 Topical fluoride varnish;Dental Varnish 30 105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for			-		13
105 81025 Urine pregnancy test 10 Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for			_		30
Vaccine for diphtheria, tetanus toxoids, acellular pertussis (whooping cough), haemophilus influenza type B, and polio for		_	·		10
(whooping cough), haemophilus influenza type B, and polio for	10.	01023		10	10
	104	00608	injection into muscle	Market+10%	Market+10%
Vaccine for diphtheria, tetanus, and acellular pertussis (whooping	100	30038		IVIAI KEL+1070	Widi Ket+1070
	10	7 00700		Market 100/	Market 100/
107 90700 cough) injection into muscle, child younger than 7 years Market+10% Market Vaccine for Hepatitis A (2 dose schedule) injection into muscle,	10	90700		IVIdi KEL+10/6	Market+10%
	100	00622		Market + 10%	Marko++100/
					Market+10% Market+10%
	103	90032	• • • • • • • • • • • • • • • • • • • •	IVIai Ket+10%	Market+10%
Vaccine for Hepatitis B (3 dose schedule) for injection into muscle,	11/	00744		Market + 100/	Marke+ 100/
110 90744 pediatric and adolescent patients Market+10% Market Vaccine for Hepatitis B adult dosage (2 dose schedule) injection Market	11(90/44		iviai Ket+10%	Market+10%
	111	00720		Market 100/	Marko+ 1100/
	111	1 30/39		ivial Ket+10%	Market+10%
Vaccine for Hepatitis B adult dosage (3 dose schedule) injection		00746		NA - 1 - 1 - 1 - 2 - 2 - 2 - 2	, , ,
	112	90/46		Market+10%	Market+10%
Vaccine for human papilloma virus (3 dose schedule) injection into		005=			
	113	90651		Market+10%	Market+10%
Vaccine for influenza administered into muscle to individuals 3		1 00000		NA= 1 1 1 200	AA 1 - 4551
			years of age and older	Market+10%	Market+10%

115	90662	Vaccine for influenza for injection into muscle	Market+10%	Market+10%
116	90672	Vaccine for influenza for nasal administration	Market+10%	Market+10%
		Vaccine for measles, mumps, and rubella (German measles)		
117	90707	injection beneath skin	Market+10%	Market+10%
118	90734	Vaccine for meningococcus injection into muscle	Market+10%	Market+10%
		Vaccine for pneumococcal polysaccharide for injection beneath the		
119	90732	skin or into muscle, patient 2 years or older	Market+10%	Market+10%
120	90713	Vaccine for polio injection beneath the skin or into muscle	Market+10%	Market+10%
121	90675	Vaccine for rabies injection into muscle	Market+10%	Market+10%
122	90681	Vaccine for Rotavirus (2 dose schedule) for oral administration	Market+10%	Market+10%
123	90736	Vaccine for shingles injection beneath skin	Market+10%	Market+10%
		Vaccine for tetanus and diphtheria toxoids injection into muscle,		
124	90714	patient 7 years or older	Market+10%	Market+10%
		Vaccine for tetanus, diphtheria toxoids and acellular pertussis		
		(whooping cough) for injection into muscle, patient 7 years or		
125	90715	older	Market+10%	Market+10%
126	90716	Vaccine for varicella (chicken pox) injection beneath skin	Market+10%	Market+10%
127	82120	Vaginal fluid chemical analysis for bacteria	6	6
		Zoster (shingles) vaccine (HZV), recombinant, sub-unit, adjuvanted,		
120	90750	for intramuscular use	Market+10%	Market+10%



Department Policy Number/Name:	County Appropriation Policy	Effective Date:	03/11/2016
Approved By:	County Administrators and Board of Health	Reviewed Date:	07/11/2023

POLICY/PURPOSE

The Mid-Michigan District Health Department (MMDHD) follows the Intergovernmental Agreement that was approved by Clinton, Gratiot and Montcalm and the State of Michigan in 2003. MMDHD will follow the agreement in developing the budgetary appropriation request for each county. The budgetary request will be based on the proposed budgetary needs for the fiscal year for MMDHD. The contribution request shall be allocated with a base amount and any increments pro-rata among the counties based on the average percentage of effort worked by each county. The effort levels will be determined by the services performed in each county which in turn should equate to staffing levels needed for each program. If there is not a way to determine services in each county the service level will be determined by population. The base amount is the appropriations that were being paid by each county in Fiscal Year 2003, the year the Intergovernmental Agreement was signed. At no point shall the funding level for any county fall below the base year regardless of the level of effort determined in the calculation.

PROCEDURE

After the budget is prepared and is ready for approval from the Board of Health, MMDHD will determine the local appropriation dollars needed from each county. The local appropriation dollars distribution between the counties will be determined by the base and then the level of effort determined by services provided in each county for the local appropriation dollars needed over the base.

MMDHD will determine the average number of services provided in each program by each county over the most recent five years. MMDHD will calculate the percentage of services in each county as compared to the district wide total. MMDHD will then apply the percentage to the local dollars needed in each program to determine a dollar amount allocated to each program from each county. The total of the allocated dollars as a percentage of the total appropriation request district wide will be applied to the additional funds requested over the base amount.

For example purposes only:	
Base allocation:	
Original Policy Date:	Supersedes Policy Date:
Original Policy Name:	Original Policy Number:



Department Policy Number/Name:	County Appropriation Policy	Effective Date:	03/11/2016
Approved By:	County Administrators and Board of Health	Reviewed Date:	07/11/2023

Clinton: \$20,000 Gratiot: \$15,000 Montcalm: \$10,000 Total: \$45,000

WIC Program – proposed budget of \$5,000 local dollars (Expenses-Revenues=Local Dollars) Clinton's services – 1,000; Gratiot services – 1,400; Montcalm – 1,600; Total services – 4,000

- Clinton level of effort based on services provided is 25%;
- Gratiot level of effort based on services provided is 35%;
- Montcalm level of effort based on services provided is 40%

Food Program – proposed budget of \$10,000 local dollars (Expenses-Revenues=Local Dollars) Clinton's services – 400; Gratiot services – 300; Montcalm – 300; Total services – 1,000

- Clinton level of effort based on services provided is 40%;
- Gratiot level of effort based on services provided is 30%;
- Montcalm level of effort based on services provided is 30%

Water Program – proposed budget of \$50,000 local dollars (Expenses-Revenues=Local Dollars) Clinton's services – 1,000; Gratiot services – 600; Montcalm – 400; Total services – 2,000

- Clinton level of effort based on services provided is 50%;
- Gratiot level of effort based on services provided is 30%;
- Montcalm level of effort based on services provided is 20%

WIC Program

Clinton (25%*\$5,000) - \$1,250 Gratiot (35%*\$5,000) - \$1,750 Montcalm (40%*\$5,000) - \$2,000

Food Program

Clinton (40%*\$10,000) - \$4,000 Gratiot (30%*\$10,000) - \$3,000 Montcalm (30%*\$10,000) - \$3,000

WIC Program

Original Policy Date:	Supersedes Policy Date:
Original Policy Name:	Original Policy Number:



Department Policy Number/Name:	County Appropriation Policy	Effective Date:	03/11/2016
Approved By:	County Administrators and Board of Health	Reviewed Date:	07/11/2023

Clinton (50%*\$50,000) - \$25,000 Gratiot (30%*\$50,000) - \$15,000 Montcalm (20%*\$50,000) - \$10,000

Clinton's level of effort proportion in the example is 47% (\$1,250+\$4,000+\$25,000=\$30,250/\$65,000) Gratiot's level of effort proportion in the example is 30% (\$1,750+\$3,000+\$15,000=\$19,750/\$65,000) Montcalm's level of effort proportion in the example is 23% (\$2,000+\$3,000+\$10,000=\$15,000/\$65,000)

The total local dollars needed in the budget is \$65,000 (\$5,000, \$10,000 and \$50,000). The base is \$45,000; therefore, the increase over the base is \$20,000 that must be spread based on level of effort.

So in the above example,

Clinton pays \$29,400 (\$20,000 base + 47% of \$20,000 (local dollars needed over base)) Gratiot pays \$21,000 (\$15,000 base + 30% of \$20,000 (local dollars needed over base)) Clinton pays \$14,600 (\$10,000 base + 23% of \$20,000 (local dollars needed over base))

Cal	lcul	lated

TOTAL SERVICES	Base		% Original Base	 opriations-	Level of Effort %	 ppriation Request	 opriation lest 23-24	Dif	ference
CLINTON	\$	329,194	36%	\$ 73,800	33%	\$ 402,994	\$ 400,645	\$	2,349
GRATIOT	\$	238,927	26%	\$ 62,600	28%	\$ 301,527	\$ 292,672	\$	8,855
MONTCALM	\$	346,475	38%	\$ 84,482	38%	\$ 430,957	\$ 442,161	\$	(11,204)
	\$	914,596	100%	\$ 220,882	100%	\$ 1,135,478	\$ 1,135,478		
Requested Appropriation 23-24	\$	1,135,478							
Base	\$	914,596							
Difference	\$	220,882							

23-24 BUDGETED - DISTRICTWIDE

					EXPENSES-REVENUE (LOCAL	
PROGRAM	Services %	ł	BUDGETED TOTAL EXPENSE	BUDGETED TOTAL REVENUE	APPROPRIATION)	CLINTON %**
General EH	37%	ł	\$ 80,343	\$ 78,000	\$ 2,343	\$ 866
SEWAGE	32%	4	\$ 705,421	\$ 568,230	\$ 137,191	\$ 43,276
WATER	28%	4	\$ 748,769	\$ 584,383	\$ 164,386	\$ 46,253
NUISANCE ABATEMENT	32%	1	\$ 43,685	\$ 500	\$ 43,185	\$ 13,697
BODY ART	32%		\$ 16,431	\$ 3,500	\$ 12,931	\$ 4,138
FOOD	36%		\$ 570,604	\$ 496,205	\$ 74,399	\$ 26,760
EH ADMINISTRATION	42%	**	\$ 79,000	\$ 79,000	\$ -	\$ -
ENVIRONMENTAL HEALTH	DIVISION TOTAL	<u>]</u>	\$ 2,244,253	\$ 1,809,818	\$ 434,435	\$ 134,989
CD	34%	1	\$ 151,583	150,609	\$ 974	\$ 330
IMMUNIZATIONS	35%	1	\$ 649,680	647,333	\$ 2,347	\$ 829
STD	31%	1	\$ 145,349	126,000	\$ 19,349	\$ 5,954
HIV	29%	1	\$ 24,264	23,500	\$ 764	\$ 221
BLOOD LEAD	32%	1	\$ 50,446	17,200	\$ 33,246	\$ 10,505
CSHCS	34%	1	\$ 332,383	261,391	\$ 70,992	\$ 24,288
CHED ADMINISTRATION	42%	**	\$ 111,000	111,000	\$ -	\$ -
COMMUNITY PATHWAYS	42%	**	\$ 111,791	111,000	\$ 791	\$ 332
FAMILY PLANNING	31%	1	\$ 370,019	324,023	\$ 45,996	\$ 14,323
HEARING	34%	1	\$ 106,981	73,235	\$ 33,746	\$ 11,399
IMMUNIZATIONS IAP	42%	**	\$ 221,652	176,075	\$ 45,577	\$ 19,142
VISION	35%	1	\$ 104,781	72,035	\$ 32,746	\$ 11,395
VARNISH	11%	1	\$ 56,949	56,000	\$ 949	\$ 109
MCIR	42%	**	\$ 30,349	30,000	\$ -	\$ -
MEDICAID OUTREACH	42%	**	\$ 170,733	87,366	\$ 83,367	\$ 35,014
WIC PROGRAMS	29%	1	\$ 989,199	837,618	\$ 151,581	\$ 43,582
ORAL HEALTH	42%	**	\$ 98,057	97,537	\$ 520	\$ 43,382
		**				
HEALTH EDUCATION	42%	1	· ·	39,500	· · · ·	· ·
BCCCP	38%	**	\$ 25,669 \$ 80,340	2,000	\$ 23,669 \$ 24,636	\$ 8,906 \$ 10,347
MCH PRENATAL & IBCLC		ł		55,704		
COMMUNITY HEALTH AND EDUCATION	DIVISION TOTAL	J	\$ 3,885,161	\$ 3,269,126	\$ 616,035	\$ 215,704
ADMINISTRATION	42%	**	\$ 298,593	\$ 298,593	\$ -	\$ -
RURAL HEALTH	42%	**	\$ -	-	\$ -	\$ -
PUBLIC HEALTH WORKFORCE	42%	**	\$ 205,856	200,100	\$ 5,756	\$ 2,418
PANDEMIC RESPONSE	42%	**	\$ 1,417,319	1,407,670	\$ 9,649	\$ 4,053
MONTCALM PREV SERVICES	0%	1	\$ 333,468	300,000	\$ 33,468	\$ -
COMMUNITY HEALTH ASSESSMENT	42%	**	\$ 15,601	10,700	\$ 4,901	\$ 2,058
DRUG FREE COMMUNITIES (CLINTON ONLY)	100%		\$ 139,138	127,000	\$ 12,138	\$ 12,138
РВВ	42%	**	\$ -	-	\$ -	\$ -
EMERGENCY PREPAREDNESS	42%	**	\$ 153,313	134,217	\$ 19,096	\$ 8,020
ADMINISTRATIVE	SERVICES TOTAL		\$ 2,563,288	\$ 2,478,280	\$ 85,008	\$ 28,687
Local Effort Percentage	33%		\$ 8,692,702	\$ 7,557,224	\$ 1,135,478	
BASE*	36%	1			\$ 914,596	\$ 329,194
LOCAL EFFORT	33%	1			\$ 220,882	\$ 73,800
	1 33%	f	6 0.003.703	ć 7.557.334		
TOTAL		1	\$ 8,692,702	\$ 7,557,224	\$ 1,135,478	\$ 402,994

^{*}Base is constant and comes from 2003 agreement

\$

^{**%} Based on service counts or population

23-24 BUDGETED - DISTRICTWIDE

		1		ĺ	1	
PROGRAM	Services %		BUDGETED TOTAL EXPENSE	BUDGETED TOTAL REVENUE	EXPENSES-REVENUE (LOCAL APPROPRIATION)	GRATIOT %**
General EH	36%		\$ 80,343	\$ 78,000	\$ 2,343	\$ 859
SEWAGE	32%		\$ 705,421	\$ 568,230	\$ 137,191	\$ 43,27
WATER	28%		\$ 748,769	\$ 584,383	\$ 164,386	\$ 46,253
NUISANCE ABATEMENT	32%		\$ 43,685	\$ 500	\$ 43,185	\$ 13,69
BODY ART	32%		\$ 16,431	\$ 3,500	\$ 12,931	\$ 4,138
FOOD	36%		\$ 570,604	\$ 496,205	\$ 74,399	\$ 26,760
EH ADMINISTRATION	23%	**	\$ 79,000	\$ 79,000	\$ -	\$ -
ENVIRONMENTAL HEALTH	DIVISION TOTAL		\$ 2,244,253	\$ 1,809,818	\$ 434,435	\$ 134,97
CD	34%	1	\$ 151,583	150,609	\$ 974	\$ 330
IMMUNIZATIONS	35%		\$ 649,680	647,333	\$ 2,347	\$ 829
STD	31%		\$ 145,349	126,000	\$ 19,349	\$ 5,954
HIV	29%		\$ 24,264	23,500	\$ 764	\$ 22
BLOOD LEAD	32%		\$ 50,446	17,200	\$ 33,246	\$ 10,50
CSHCS	34%		\$ 332,383	261,391	\$ 70,992	\$ 24,28
CHED ADMINISTRATION	23%	**	\$ 111,000	111,000	\$ -	\$ -
COMMUNITY PATHWAYS	23%	**	\$ 111,791	111,000	\$ 791	\$ 183
FAMILY PLANNING	31%		\$ 370,019	324,023	\$ 45,996	\$ 14,32
HEARING	34%		\$ 106,981	73,235	\$ 33,746	\$ 11,39
IMMUNIZATIONS IAP	23%	**	\$ 221,652	176,075	\$ 45,577	\$ 10,48
VISION	35%		\$ 104,781	72,035	\$ 32,746	\$ 11,39
VARNISH	11%		\$ 56,949	56,000	\$ 949	\$ 10.
MCIR	23%	**	\$ 30,949	30,000	\$ -	\$ -
MEDICAID OUTREACH	23%	**	\$ 170,733	87,366	\$ 83,367	\$ 19,174
WIC PROGRAMS	29%		\$ 989,199	837,618	\$ 151,581	\$ 43,58
ORAL HEALTH	23%	**	\$ 98,057	97,537	\$ 520	\$ 120
HEALTH EDUCATION	23%	**	\$ 84,285	39,500	\$ 44,785	\$ 10,30
BCCCP	38%		\$ 25,669	2,000	\$ 23,669	\$ 8,90
MCH PRENATAL & IBCLC	23%	**	\$ 80,340	55,704	\$ 24,636	\$ 5,66
COMMUNITY HEALTH AND EDUCATION	I		\$ 3,885,161		\$ 616,035	\$ 177,76
	-	1		Ι.		
ADMINISTRATION	23%	1				\$ -
RURAL HEALTH	23%	**	\$ -	-	\$ -	\$ -
PUBLIC HEALTH WORKFORCE	23%	**	\$ 205,856	200,100		\$ 1,324
PANDEMIC RESPONSE	23%	**	\$ 1,417,319	1,407,670		\$ 2,219
MONTCALM PREV SERVICES	0%		\$ 333,468	300,000		\$ -
COMMUNITY HEALTH ASSESSMENT	23%	**	\$ 15,601	10,700	\$ 4,901	\$ 1,12
DRUG FREE COMMUNITIES (CLINTON ONLY)	0%		\$ 139,138	127,000	\$ 12,138	\$ -
PBB	23%	**	\$ -	-	\$ -	\$ -
EMERGENCY PREPAREDNESS	23%	**	\$ 153,313	134,217	\$ 19,096	\$ 4,39.
ADMINISTRATIVE			\$ 2,563,288			\$ 9,062
Local Effort Percentage	28%]	\$ 8,692,702	\$ 7,557,224	\$ 1,135,478	
BASE*	26%				\$ 914,596	\$ 238,927
LOCAL EFFORT	28%				\$ 220,882	\$ 62,600
TOTAL			\$ 8,692,702	\$ 7,557,224	\$ 1,135,478	\$ 301,522

^{*}Base is constant and comes from 2003 agreement

^{**%} Based on service counts or population

23-24 BUDGETED - DISTRICTWIDE

SENDAGE 375 5 50,656 5 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 5 50,656 137,191 137,191 5 50,656 137,191 137,	PROGRAM	Services %		BUDGETED TOTAL EXPENSE	BUDGETED TOTAL REVENUE	EXPENSES-REVENUE (LOCAL APPROPRIATION)	MONTCALM %**	
NATER	General EH	27%		\$ 80,343	\$ 78,000	\$ 2,343	\$	623
STATEMENT 375 5 43,685 5 500 5 43,185 5 15,795	SEWAGE	37%		\$ 705,421	\$ 568,230	\$ 137,191	\$	50,639
Section Sect	WATER	44%		\$ 748,769	\$ 584,383	\$ 164,386	\$	71,881
Second S	NUISANCE ABATEMENT	37%		\$ 43,685	\$ 500	\$ 43,185	\$	15,791
ENDINGNIMENTAL HEALTH DIVISION TOTAL	BODY ART	36%		\$ 16,431	\$ 3,500	\$ 12,931	\$	4,655
S	FOOD	28%		\$ 570,604	\$ 496,205	\$ 74,399	\$	20,880
STO 328	EH ADMINISTRATION	35%	**	\$ 79,000	\$ 79,000	\$ -	\$	-
MMUNIZATIONS	ENVIRONMENTAL HEALTH	DIVISION TOTAL]	\$ 2,244,253	\$ 1,809,818	\$ 434,435	\$	164,469
STD	CD	32%		\$ 151,583	150,609	\$ 974	\$	314
HIV	IMMUNIZATIONS	29%		\$ 649,680	647,333	\$ 2,347	\$	689
Series S	STD	38%		\$ 145,349	126,000	\$ 19,349	\$	7,442
STATE	ніу	42%		\$ 24,264	23,500	\$ 764	\$	323
S	BLOOD LEAD/CM	37%		\$ 50,446	17,200	\$ 33,246	\$	12,236
COMMUNITY PATHWAYS	CSHCS	32%		\$ 332,383	261,391	\$ 70,992	\$	22,415
RAMILY PLANNING	CHED ADMINISTRATION	35%	**	\$ 111,000	111,000	\$ -	\$	-
HEARING	COMMUNITY PATHWAYS	35%	**	\$ 111,791	111,000	\$ 791	\$	277
MMUNIZATIONS IAP 35% 15,952 16,075 45,577 5 15,955 15,955 104,781 72,035 5 32,746 5 9,556 104,781 72,035 5 32,746 5 9,556 104,781 72,035 5 32,746 5 9,556 104,781 72,035 5 32,746 5 9,556 104,781 72,035 5 32,746 5 9,556 104,781 72,035 5 32,746 5 9,556 104,781 72,035 5 32,746 5 9,556 104,781 72,035 5 32,746 5 9,556 104,781 72,035 5 32,746 5 9,556 5 733 104,781 72,035 5 32,746 5 9,556 5 733 104,781 72,035 5 32,746 5 9,556 5 733 104,781 72,035 5 32,746 5 9,556 5 733 104,781 72,035 5 32,746 5 9,556 5 733 104,781 72,035 5 32,746 5 9,556 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 5 32,746 5 733 104,781 72,035 73,737 5 733 733 733 733 734,786 733 733 734,786 733 733 734,786 733 733 734,786 733 733 734,786 733 733 734,786 733 733 734,786 733 733 734,786 733 733 734,786 733 733 734,786 733 733 734,786 733 734,786 733 734,786 733 734,786 733 734,786 733 734,786 734,	FAMILY PLANNING	38%		\$ 370,019	324,023	\$ 45,996	\$	17,351
S	HEARING	32%		\$ 106,981	73,235	\$ 33,746	\$	10,948
VARNISH	IMMUNIZATIONS IAP	35%	**	\$ 221,652	176,075	\$ 45,577	\$	15,952
MCIR	VISION	30%		\$ 104,781	72,035	\$ 32,746	\$	9,956
MEDICAID OUTREACH 35% WICE PROGRAMS 42% ORAL HEALTH COURTION 35% BCCCP 25% S 84,285 39,500 \$ 44,785 \$ 15,575 \$ 5,20 \$ 1,875 \$ 5,20 \$ 1,875 \$ 1	VARNISH	77%		\$ 56,949	56,000	\$ 949	\$	731
WIC PROGRAMS	MCIR	35%	**	\$ -		\$ -	\$	-
ORAL HEALTH 35% \$ 98,057 97,537 \$ 520 \$ 182 HEALTH EDUCATION 35% \$ 84,285 39,500 \$ 44,785 \$ 15,675 BCCCP 25% \$ 25,669 2,000 \$ 23,669 \$ 5,856 IMMUNIZATIONS WAIVER 35% \$ 80,340 55,704 \$ 24,636 \$ 36,623 COMMUNITY HEALTH AND EDUCATION DIVISION TOTAL \$ 298,593 \$ 298,593 \$ \$ 616,035 \$ 222,566 ADMINISTRATION 35% * \$ 298,593 \$ 298,593 \$	MEDICAID OUTREACH	35%	**	\$ 170,733	87,366	\$ 83,367	\$	29,178
## S	WIC PROGRAMS	42%		\$ 989,199	837,618	\$ 151,581	\$	64,418
S	ORAL HEALTH	35%	**	\$ 98,057	97,537	\$ 520	\$	182
S	HEALTH EDUCATION	35%	**	\$ 84,285	39,500	\$ 44,785	\$	15,675
S 3,885,161 S 3,269,126 S 616,035 S 222,566	ВСССР	25%		\$ 25,669	2,000	\$ 23,669	\$	5,856
ADMINISTRATION 35% ** \$ 298,593 \$ 298,593 \$ - \$ \$ \$ - \$ \$ \$ \$ - \$	IMMUNIZATIONS WAIVER	35%	**	\$ 80,340	55,704	\$ 24,636	\$	8,623
RURAL HEALTH	COMMUNITY HEALTH AND EDUCATION	DIVISION TOTAL		\$ 3,885,161	\$ 3,269,126	\$ 616,035	\$	222,566
## S	ADMINISTRATION	35%	**	\$ 298,593	\$ 298,593	\$ -	\$	-
## S	RURAL HEALTH	35%	**	\$ -	-	\$ -	\$	-
S S S S S S S S S S	PUBLIC HEALTH WORKFORCE	35%	**	\$ 205,856	200,100	\$ 5,756	\$	2,015
COMMUNITY HEALTH ASSESSMENT 35% ** \$ 15,601 10,700 \$ 4,901 \$ 1,715 \$	EMERGING THREATS/PANDEMIC RESPONSE	35%	**	\$ 1,417,319	1,407,670	\$ 9,649	\$	3,377
DRUG FREE COMMUNITIES (CLINTON ONLY) 0% PBB 35% *** \$ 139,138 127,000 \$ 12,138 S - - \$ - S 153,313 134,217 \$ 19,096 ADMINISTRATIVE SERVICES TOTAL \$ 2,563,288 \$ 2,478,280 \$ 85,008 Local Effort Percentage 38% \$ 8,692,702 \$ 7,557,224 \$ 1,135,478 BASE* 38% \$ 914,596 \$ 346,475 LOCAL EFFORT 38% \$ 220,882 \$ 84,482	MONTCALM PREV SERVICES	100%		\$ 333,468	300,000	\$ 33,468	\$	33,468
PBB 35% ** \$ \$	COMMUNITY HEALTH ASSESSMENT	35%	**	\$ 15,601	10,700	\$ 4,901	\$	1,715
## \$ 153,313	DRUG FREE COMMUNITIES (CLINTON ONLY)	0%		\$ 139,138	127,000	\$ 12,138	\$	-
Sample Services total Sample Sa	РВВ	35%	**	\$ -	-	\$ -	\$	-
Second Effort Percentage 38% Second Seco	EMERGENCY PREPAREDNESS	35%	**	\$ 153,313	134,217	\$ 19,096	\$	6,684
BASE* 38% \$ 914,596 \$ 346,475 LOCAL EFFORT 38% \$ 220,882 \$ 84,482	ADMINISTRATIVE :	SERVICES TOTAL		\$ 2,563,288	\$ 2,478,280	\$ 85,008	\$	47,259
LOCAL EFFORT 38% \$ 220,882 \$ \$4,482	Local Effort Percentage	38%		\$ 8,692,702	\$ 7,557,224	\$ 1,135,478		
	BASE*	38%				\$ 914,596	\$	346,475
TOTAL \$ 8,692,702 \$ 7,557,224 \$ 1,135,478 \$ 430,957	LOCAL EFFORT	38%				\$ 220,882	\$	84,482
	TOTAL			\$ 8,692,702	\$ 7,557,224	\$ 1,135,478	\$	430,957

^{*}Base is constant and comes from 2003 agreement

^{**%} Based on service counts or population

Report to the Boards of Health

Jennifer Morse, MD, MPH, FAAFP, Medical Director



Mid-Michigan District Health Department, Wednesday, July 26, 2023
District Health Department 10, Friday, July 28, 2023


Air Quality

Wildfire smoke creates air pollution that can be a health hazard. The main pollutant from smoke is particulate pollution also called particulate matter. Other pollutants include carbon monoxide, ozone, hydrocarbons, and other organic chemicals, especially if buildings and man-made materials are burning.

Particulate matter (PM) is a general term for a mixture of solid and liquid droplets that can hang in the air. Particles 10 micrometers (μ m) wide or smaller can be breathed in through the nose and throat and go into the lungs. Particles 2.5 μ m and smaller can even get into the bloodstream. Particles from smoke are usually very small, many less than 1 μ m.

Particulate matter and air pollution from wildfires can irritate the eyes and airways. It can also cause increased illness and early death from

- Asthma
- Bronchitis
- COPD
- Pneumonia
- Abnormal heart rhythms
- Heart attack
- Congestive heart failure
- Sudden cardiac arrest
- Stroke



Life stages and situations that are at higher risk from this exposure include:

- Children
 - Children spend more time outdoors and are usually at a greater activity level than adults.
 - The amount of air children inhale per pound of body weight compared to adults is higher, so they have a higher among of exposure compared to adults.
 - Children's lungs are still developing and more easily damaged. Some damage can be irreversible.
 - Children are more likely to have asthma than adults.
- Older adulthood (65 years of age and older)
 - Older adults are more likely to have pre-existing respiratory or cardiovascular diseases. There is also a decline in the body's defenses that occur as part of the aging process.
- Pregnant women
 - Pregnant women have a higher breathing rate, causing them to have a higher amount of exposure.
 - Exposures to the mother may affect the developing fetus.
 - Some evidence from wildfire smoke, and evidence from secondhand tobacco smoke exposure, show risks of lower birth weight with exposure to particulate matter prior to birth.
- Outdoor workers
 - Outdoor workers have longer periods of time exposed to smoke which can lead to increased risks of experiencing health effects.
- People with lower socioeconomic status (SES)

- Those with lower SES typically have higher amounts of pre-existing health conditions and less access to medical care. This leads to a higher likelihood of untreated or insufficiently treated underlying health conditions.
- They have less access to measures to reduce exposure, such as air conditioning or air filtration, which could lead to higher levels of exposure.
- They may be exposed to higher levels of other pollutants due to the location of their homes, schools, and work environments.
- People with pre-existing health problems, specifically lung disease, cardiovascular diseases, and diabetes.

Healthy people can also be affected, especially if they are more active while outside, or are more sensitive to smoke.

Health Resources:

- Air Quality Index A Guide to Air Quality and Your Health https://www.airnow.gov/sites/default/files/2018-04/agi brochure 02 14 0.pdf
- Particle Pollution and Your Health https://www.airnow.gov/sites/default/files/2018-03/pm-color.pdf
- Protecting Children from Wildfire Smoke and Ash https://www.airnow.gov/sites/default/files/2021-07/pehsu-protecting-children-from-wildfire-smoke-and-ash-factsheet.pdf
- How Smoke from Fires Can Affect Your Health https://www.airnow.gov/sites/default/files/2021-08/how-smoke-from-fire-can-affect-your-health-2021-v1-d1.pdf

For pets and animals:

- Protect Your Large Animals and Livestock from Wildfire Smoke
 https://www.airnow.gov/sites/default/files/2021-06/protect-your-large-animals-and-livestock-from-wildfire-smoke.pdf
- Protect Your Pets from Wildfire Smoke https://www.airnow.gov/sites/default/files/2021-06/protect-your-pets-from-wildfire-smoke.pdf

Action Steps

For the General Public:

- 1. Sign up and Start Receiving Your Air Quality Forecast https://www.enviroflash.info/signup.cfm
 - a. Air Quality Guide for Particle Pollution https://www.airnow.gov/sites/default/files/2023-03/air-quality-guide-for-particle-pollution_0.pdf
- 2. Prepare for Fire Season https://www.airnow.gov/sites/default/files/2021-07/prepare-for-fire-season.pdf
- 3. Reduce Your Smoke Exposure https://www.airnow.gov/sites/default/files/2021-07/reduce-your-smoke-exposure.pdf
 - a. Infographic: Reduce Health Risks In Areas With Wildfire Smoke https://www.airnow.gov/sites/default/files/2020-02/reduce-health-risks-with-wildfire-smoke-508.pdf
 - b. Create a Clean Room to Protect Indoor Air Quality During a Wildfire https://www.epa.gov/indoor-air-quality-during-wildfire OR https://www.airnow.gov/sites/default/files/2022-02/how-to-create-a-clean-room-at-home.pdf
 - c. Indoor Air Filtration https://www.airnow.gov/sites/default/files/2022-02/indoor-air-filtration.pdf
 - d. U.S. EPA: Guide to Air Cleaners in the Home https://www.epa.gov/sites/default/files/2018-07/documents/guide to air cleaners in the home 2nd edition.pdf
 - e. DIY Air Cleaner to Reduce Wildfire Smoke Indoors https://www.epa.gov/system/files/documents/2021-09/diy-air-purifier-infographic_final.pdf
- 4. Protect Your Lungs from Wildfire Smoke or Ash (Masks) https://www.airnow.gov/sites/default/files/2021-12/protect-your-lungs-from-wildfire-smoke-or-ash.pdf

5. Take care of your health. See: How Smoke from Fires Can Affect Your Health https://www.airnow.gov/sites/default/files/2021-08/how-smoke-from-fire-can-affect-your-health-2021-v1-d1.pdf

For Government Agencies/Businesses/Public Health:

- 1. Sign up and Start Receiving Your Air Quality Forecast https://www.enviroflash.info/signup.cfm
 - a. Other forecasting tools:
 - i. 84 hr. forecast https://tools.airfire.org/websky/v2/run/standard/NAM84-0.15deg/2023070700/#viewer
 - ii. Fire Potential Outlooks https://www.nifc.gov/nicc/predictive-services/outlooks
 - iii. NASA Fire and Smoke mapping https://www.ospo.noaa.gov/Products/land/hms.html#maps
 - iv. Other Wildland Fire / Air Quality Tools https://portal.airfire.org/
- 2. Wildfire Smoke: A Guide for Public Health Officials https://www.airnow.gov/publications/wildfire-smoke-guide/wildfire-smoke-a-guide-for-public-health-officials/
- 3. Consider setting up an air quality/smoke page. Example: https://wasmoke.blogspot.com/
- 4. Health effects of Common Air Pollutants Poster https://www.airnow.gov/sites/default/files/2018-03/common-air-pollutants-2011-lo.pdf
- 5. Employee and public building Health
 - a. Occupational Safety and Health Administration Wildfires https://www.osha.gov/wildfires
 - b. Outdoor Workers Exposed to Wildfire Smoke https://www.cdc.gov/niosh/topics/firefighting/wffsmoke.html
 - c. Protecting Outdoor Workers Exposed to Smoke from Wildfires https://www.dir.ca.gov/dosh/wildfire/Worker-Protection-from-Wildfire-Smoke.html
 - d. Wildfires and Indoor Air Quality in Schools and Commercial Buildings
 https://www.epa.gov/indoor-air-quality-iaq/wildfires-and-indoor-air-quality-schools-and-commercial-buildings
 - e. ASHRAE: Planning Framework for Protecting Commercial Building Occupants from Smoke During Wildfire Events https://www.ashrae.org/file%20library/technical%20resources/covid-19/guidance-for-commercial-building-occupants-from-smoke-during-wildfire-events.pdf
- 6. School Information
 - a. U.S. EPA: Air Quality and Outdoor Activity Guidance for Schools: Indoor Air Quality, A Guide for Educators https://www.cde.ca.gov/ls/fa/sf/iaq.asp
 - b. Air Quality Guidance Template for Schools https://www.aqmd.gov/docs/default-source/air-quality/advisories/air-quality-guidance-for-schools.pdf?sfvrsn=6
- 7. Respirators
 - a. NIOSH Respirator Trusted-Source Information https://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/RespSource.html
 - b. Non-occupational Uses of Respiratory Protection What Public Health Organizations and Users Need to Know https://blogs.cdc.gov/niosh-science-blog/2018/01/04/respirators-public-use/
- ➤ Keep in mind that one of the main sources of particulate matter in the winter months in Michigan are wood burning units used for heat (https://www.ladco.org/public-issues/great-lakes-air-quality/).
 - The EPA has resources to help educate the public and businesses to reduce the risks with wood burning for heat at https://www.epa.gov/burnwise.
 - Also the state has provided an "Outdoor Burning Model Ordinance A Guide for Michigan Counties,
 Cities, Villages, and Townships" which includes verbiage for Outdoor Wood Furnaces available at
 https://www.michigan.gov/documents/deq/deq-ess-caap-modelordinance_312507_7.pdf

Health effects, public messages, and recommended actions for each AQI category NOTE: Higher advisory levels automatically incorporate all of the guidance offered at lower levels					
AQI Category (AQI Values)	Flag Color	Health Effects	Warning Messages	Other Action Step Messages for Public	Recommended Actions for Consideration
Good (0–50)	green	None expected	None	None	If smoke event forecasted, implement communication plan. Example: Public Health Wildfire Smoke Communication Guide, Montana
Moderate (51–100)	yellow	Possible aggravation of heart or lung disease	Unusually sensitive people should consider limiting prolonged or heavy exertion/activity. People with heart or lung disease should pay attention to symptoms. Individuals with symptoms of lung or heart disease (repeated coughing, shortness of breath or difficulty breathing, wheezing, chest tightness or pain, palpitations, nausea, unusual fatigue or lightheadedness) should contact a health care provider.	If having symptoms, reduce exposure by following advice in box below.	Prepare for full implementation of School Activity Guidelines (https://www.airnow.gov/sites/default/files/2021-03/school-outdoor%20activity%20guidance.pdf). Issue public service announcements (PSAs) advising public about health effects, symptoms, and ways to reduce exposure. Distribute information about exposure avoidance.
Unhealthy for Sensitive Groups (101–150)	orange	Increasing likelihood of respiratory or cardiac symptoms in sensitive individuals, aggravation of heart or lung disease, and premature death in people with heart or lung disease and older adults.	Sensitive Groups (People with heart or lung disease, the elderly, children, and pregnant women) should: Limit time spent outdoors. Avoid physical exertion/activity. People with asthma should follow their asthma management plan. Individuals with symptoms of lung or heart disease that may be related to excess smoke exposure (repeated coughing, shortness of breath or difficulty breathing, wheezing, chest tightness or pain, heart palpitations, nausea, unusual fatigue or lightheadedness) should contact a health care provider.	 Keep doors and windows closed, seal large gaps as much as possible. Avoid using exhaust fans (e.g., kitchen, bathroom, clothes dryer, and utility room exhaust fans). If cooling is needed, turn air conditioning to recirculate mode in home and car, or use ceiling fans or portable fans. Turn fans to recirculate mode. If a home has a central heating and/or air conditioning system, install higher-efficiency filters (e.g., filters rated at MERV 13 or higher) if they can be accommodated by the system. The system's circulating fan can be temporarily set to operate continuously to obtain maximum particle removal by the central air system's filter, although this will increase energy use and costs. Operate appropriately sized portable air cleaners to reduce indoor particle levels. Avoid indoor sources of pollutants, including tobacco smoke, heating with wood stoves and kerosene heaters, frying or broiling foods, burning candles or incense, vacuuming (unless with HEPA filter), using paints, solvents, cleaning products, and adhesives. Keep at least a 5-day supply of medication available and have a supply of non-perishable groceries to avoid leaving the home. 	

AQI Category (AQI Values)	Flag Color	Health Effects	Warning Messages	Other Action Step Messages for Public	Recommended Actions for Consideration
Unhealthy (151–200)	red	Increased aggravation of heart or lung disease and premature death in persons with heart or lung disease and older adults; increased respiratory effects in general population.	Sensitive Groups: Should avoid prolonged or heavy exertion/activity. Everyone: Should limit prolonged or heavy exertion/activity. Limit time spent outdoors. Individuals with symptoms of lung or heart disease that may be related to excess smoke exposure (repeated coughing, shortness of breath or difficulty breathing, wheezing, chest tightness or pain, palpitations, nausea or unusual fatigue or lightheadedness) should contact your health care provider.	Sensitive Groups: Stay in a "clean room" at home. Everyone: Follow advice for sensitive groups in box above. Identify potential "cleaner air" shelters in the community.	Full implementation of <u>School Activity Guidelines</u> Consider canceling outdoor events (e.g., concerts and competitive sports), based on public health and travel considerations.
Very Unhealthy (201–300)	purple	Significant aggravation of heart or lung disease, premature death in persons with heart or lung disease and older adults; significant increase in respiratory effects in general population.	Everyone: Should avoid prolonged or heavy exertion/activity and stay indoors, preferably in a space with filtered air.	Everyone: If symptomatic, seek medical attention. If you are unable to create your own cleaner indoor air space to shelter in place, evacuate to a cleaner air shelter or leave the area, if it is safe to do so.	 Move all school activities indoors or reschedule them to another day. Cancel school physical activities (e.g., physical education, athletic practice) unless the school is able to provide cleaner indoor air for the students. Consider closing some or all schools. Cancel outdoor events involving activity (e.g., competitive sports). Consider canceling outdoor events that do not involve activity (e.g. concerts).
Hazardous (> 300)	Wildfire Smoke Workshop: W	Serious aggravation of heart or lung disease, premature death in persons with heart or lung disease and older adults; serious risk of respiratory effects in general population.	Everyone: Should avoid any outdoor activity, and stay indoors, preferably in a space with filtered air. //www.airnow.gov/sites/default/files/2022-01/childrens-he	Everyone: If symptomatic, seek medical attention. If you are unable to create your own cleaner indoor air space to shelter in place, evacuate to a cleaner air shelter or leave the area, if it is safe to do so. Application of the state of the stat	Consider closing schools¹. Cancel outdoor events (e.g., concerts and competitive sports). Consider air quality in indoor workplaces and take measures to protect workers as needed. See Appendix D of Wildfire Smoke: A Guide for Public Health Officials Consider curtailment of outdoor work activities unless the workers have a fully implemented respirator plan in place and clean air respite breaks. If PM levels are projected to remain high for a prolonged time, consider evacuation of at-risk populations.

1 See Children's Health and Wildfire Smoke Workshop: Workshop Recommendations https://www.airnow.gov/sites/default/files/2022-01/childrens-health-wildfire-smoke-workshop-recommendations https://www.airnow.gov/sites/default/files/2022-01/childrens-health-wildfire-smoke-workshop-recommendations https://www.airnow.gov/sites/default/files/2022-01/childrens-health-wildfire-smoke-workshop-recommendations https://www.airnow.gov/sites/default/files/2022-01/childrens-health-wildfire-smoke-workshop-recommendations https://www.airnow.gov/sites/default/files/2022-01/childrens-health-wildfire-smoke-a-guide-for-public-health-officials/ https://www.airnow.gov/sites/default/files/2022-01/childrens-health-wildfire-smoke-a-guide-for-public-health-officials/ <a href="https://www.airnow.gov/sites/airnow.go

Recommendations:

- 1. Sign up and Start Receiving Your Air Quality Forecast https://www.enviroflash.info/signup.cfm
- 2. Be prepared for poor air quality days. Develop a plan for yourself and your community before fire season starts.

Sources

- Wildfire Smoke: A Guide for Public Health Officials https://www.airnow.gov/publications/wildfire-smoke-guide/wildfire-smoke-a-guide-for-public-health-officials/
- As referenced in text




CLINTON • GRATIOT • MONTCALM

Quarterly Service Report

3rd Quarter 2022-2023 Totals presented to BOH


July 26, 2023

WIC






Family Planning






Immunizations






Food Service Sanitation Program






Onsite Wastewater Program






Drinking Water Program





Nuisance Complaints





Quarterly Service Report

Mid-Michigan District Health Department Community Health & Education Services

QTR Verified by Div Dir

1st 2nd 3rd 4th

x x x

District Wide (DW)

COMMUNITY HEALTH & EDUCATION PROGRAMS	Cli	nton 20	022/20)23	Gra	tiot 20)22/20)23	Mon	tcalm	2022/2	2023	D\	N Year 2022/		e	YTD FY FY		DW I	Prev. Ye 2021/2		ate
EDUCATION FROGRAMS	1st	2nd	3rd	4th	1st	2nd	3rd	4th	1st	2nd	3rd	4th	1st	2nd	3rd	4th	Total	Joan	1st	2nd	3rd	4th
WOMEN, INFANTS & CHILDREN																						
A. Clients Served	639	619	619		853	898	931		1511	1515	1522		3003	3032	3072	0	3036	3099	2949	3031	3043	2942
B. Client Visits	627	688	743		677	595	935		1543	1849	1761		2847	3132	3439	0	9418	12000	3156	3541	3488	3088
FAMILY PLANNING																						
A. Clients Served	26	46	36		44	61	62		49	45	34		119	152	132	0	282	700	156	186	136	139
B. Client Visits	27	48	41		44	65	69		58	45	38		129	158	148	0	435	1000	162	208	155	148
IMMUNIZATION																						
A. Clients Served	306	177	111		324	100	85		303	139	103		933	416	299	0	1450	3000	1473	625	601	896
B. Client Visits	372	199	124		384	126	93		357	187	118		1113	512	335	0	1960	3200	1802	765	760	1067
C. Waivers Provided	20	25	20		22	5	4		52	12	29		94	42		0	189	N/A	68	48	39	261
D. Immunizations Administered	712	456	292		691	289	191		548	352	209		1951	1097	692	0	3740	5700	2283	1298	1213	1630
CHILDREN SPECIAL HEALTH CARE																						
A. Clients Served	140	148	130		92	103	94		205	203	202		437	454	426	0	925	720	444	437	438	472
B. Billable Client Contacts	11	12	28		19	24	13		32	24	12		62	60	53	0	175	360	58	66	79	52
C. Non-Billable Client Contacts	301	350	363		250	267	251		386	395	415		937	1012	1029	0	2978	2500	983	1053	1115	1103
COMMUNICABLE DISEASE/TB CONTROL																						
A. Case Count	1969	1301	533		710	803	297		1011	590	273		3690	2694	1103	0	7487	N/A	13282	13683	4529	5445
SEXUALLY TRANSMITTED DISEASE CONTROL																						
A. Clients Served	9	20	9		8	13	16		18	12	9		35	45	34	0	80	N/A	47	45	30	24
B. Client Visits	9	21	9		8	14	16		18	20	9		35	55	34	0	124	N/A	47	45	30	24

Quarterly Service Report

Mid-Michigan District Health Department Community Health & Education Services

QTR Verified by Div Dir									
1st 2nd 3rd 4th									

District Wide (DW)

COMMUNITY HEALTH & EDUCATION PROGRAMS	Cli	nton 2	022/20	23	Gra	Gratiot 2022/2023			Mon	tcalm	2022/2	2023	D\	N Year ⁻ 2022/2		9	YTD FY Goal	FY Goal	DW P	rev. Ye 2021/2		ate
EDUCATION PROGRAMS	1st	2nd	3rd	4th	1st	2nd	3rd	4th	1st	2nd	3rd	4th	1st	2nd	3rd	4th	Goai	Goai	1st	2nd	3rd	4th
HEARING SCREENING																						
A. # of Screenings	846	908	469		471	679	325		1526	1429	1080		2843	3016	1874	0	7733	8000	2124	3126	2548	1031
VISION SCREENING																						
A. # of Screenings	993	1588	1680		607	1130	796		2114	2735	1052		3714	5453	3528	0	12695	12200	2971	4090	3548	1323
ORAL HEALTH																						
A. # of fluoride varnish Clients Served during Clinic	0	0	0		1	0	0		4	38	11		5	38	11	0	54	600	0	0	0	22
B. # of kindergarten assessments	265	16	102		183	2	79		363	74	158		811	92	339	0	1242	700	N/A	N/A	N/A	N/A
BLOOD LEAD																						
A. # of elevated BL levels (VBLL ≥3.5)	3	1	3		1	0	0		2	1	7		6	2	10	0	18	N/A	N/A	N/A	N/A	N/A
B. # in case management	1	3	1		1	1	2		0	6	1		2	10	4	0	16	N/A	N/A	N/A	N/A	N/A
BREAST & CERVICAL CANCER CONTROL																						
A. Clients Served	4	0	1		3	2	0						7	2	1	0	10	30	9	6	2	5
HIV SCREENING																						
A. Clients Served	7	12	13		8	13	12		11	11	6		26	36	31	0	93	N/A	33	27	24	19

NOTES

STD: there were 3 clients served/3 visits from Shiawassee that were not included in the data.

FP: there were 6 clients & 7 visits from Shiawassee that were not included in the data.

Quarterly Service Report

Mid-Michigan District Health Department Environmental Health Services

QTR Verified by Div Dir

1st 2nd 3rd 4th

x x x

District Wide (DW)

ENIVRONMENTAL HEALTH PROGRAMS	Clir	nton 20	022/20	23		itiot 20)22/2(,	Mon	tcalm	2022/2		D\	V Year 2022/		te	YTD FY	FY Goal	DW F	2021/		
	1st	2nd	3rd	4th	1st	2nd	3rd	4th	1st	2nd	3rd	4th	1st	2nd	3rd	4th	Total		1st	2nd	3rd	4th
FOOD SERVICE SANITATION																						
A. # of Licensed Establishments (Fixed,																						
Mobile)	200	202	199		134	132	132		206	206	204		540	540	535	0	535	535	534	534	530	
B. # of Temporary Food Licenses	11	4	12		17	1	6		5	3	42		33	8	60	0	101	176	25	2	22	54
C. # of Completed Inspections (Fixed,																						
Mobile)	95	109	107		56	87	64		95	98	123		246	294	294	0	834	N/A	216	307	265	369
1. Routine	78	95	95		37	73	58		88	89	119		203	257	272	0	732	N/A	188	253	230	310
2. Follow-up	17	14	12		9	14	6		7	9	4		33	37	22	0	92	N/A	28	54	35	59
E. Licensed Establishment Plan Review	2	3	10		3	4	4		2	6	7		7	13	21	0	41	24	3	7	18	6
F. Enforcement Activities	0	0	0		0	0	1		0	0	3		0	0	4	0	4	N/A	0	0	0	0
G. # of Advanced Food Training																		,				
Participants	25	24	25		24	7	25		24	0	26		73	31	76	0	180	TBD	25	22	73	36
ON-SITE SEWAGE DISPOSAL																						
A. # of Permit Applications Issued	18	23	48		17	10	25		60	43	63		95	76	136	0	307	553	104	76	172	150
B. Parcels Evaluated	29	38	61		23	20	39		77	62	82		129	120	182	0	431	612	168	101	206	169
C. Inspections Conducted during																						
and/or after construction	44	12	34		32	14	46		70	41	70		146	67	150	0	363	N/A	136	55	93	211
WATER QUALITY CONTROL																						
(Private, Public, Non-Comm)																						
A. # of Permit Applications Issued	19	21	45		22	11	25		72	62	79		113	94	149	0	356	686	139	114	162	191
B. # of Site Inspections of Completed																						
Water Well Systems	19	20	18		16	16	26		52	48	52		87	84	96	0	267	100%	89	79	48	101
C. # of Approvals Issued for Newly																						
Completed Water Well Systems	24	15	3		22	22	6		70	26	9		116	63	18	0	197	80%	80	55	56	107
NUISANCE ABATEMENT																						
A. # of Complaints Submitted	9	8	15		5	5	14		22	15	29		36	28	58	0	122	N/A	27	38	44	46
1. Initial Visit	7	5	8		7	6	12		14	11	17		28	22	37	0	87	N/A	12	25	29	39
2. Follow-up Visit	1	6	3		1	5	13		7	15	6		9	26	22	0	57	N/A	11	12	19	24

MMDHD 3rd Quarter QSR for Clinton County

COMMUNITY HEALTH &	Clin	ton County	/ 3 rd Quarte	er
EDUCATION PROGRAMS	22/23	21/22	20/21	19/20
WOMEN, INFANTS & CHILDREN				
A. Clients Served	619	633	619	733
B. Client Visits	743	684	0	607
FAMILY PLANNING				
A. Clients Served	36	37	48	63
B. Client Visits	41	43	51	68
IMMUNIZATION				
A. Clients Served	111	252	1471	54
B. Client Visits	124	317	2328	55
C. Waivers Provided	20	28	N/A	N/A
D. Immunizations Administered	292	562	2429	117
CHILDREN SPECIAL HEALTH CARE				
A. Clients Served	130	150	157	129
B. Billable Client Contacts	28	40	27	14
D. Non-Billable Client Contacts	363	451	336	217
COMMUNICABLE DISEASE/TB CONTROL				
A. Case Count	533	2535	1845	1879
SEXUALLY TRANSMITTED DISEASE CONTROL				
A. Clients Served	9	7	15	4
B. Client Visits	9	7	15	4

COMMUNITY HEALTH &	Clin	ton County	y 3 rd Quarte	er
EDUCATION PROGRAMS	22/23	21/22	20/21	19/20
HEARING SCREENING				
A. # of Screenings	469	1230	169	0
VISION SCREENING				
A. # of Screenings	1680	1148	182	0
ORAL HEALTH				
A. # of Clients Served during Clinic	0	0	2	0
B. # of kindergarten assessments	102	N/A	N/A	N/A
BLOOD LEAD				
A. # of elevated BL levels (VBLL ≥3.5)	3	N/A	N/A	N/A
B. # in case management	1	N/A	N/A	N/A
BREAST & CERVICAL CANCER CONTROL				
A. Clients Served	1	1	1	1
HIV SCREENING				
A. Clients Served	13	7	6	0

MMDHD 3rd Quarter QSR for Clinton County

ENIVRONMENTAL HEALTH	Clint	ton County	y 3 rd Quai	rter
PROGRAMS	22/23	21/22	20/21	19/20
FOOD SERVICE SANITATION				
A. # of Licensed Establishments (Fixed, Mobile)	199	202	205	209
B. # of Temporary Food Licenses	12	1	2	0
C. # of Completed Inspections (Fixed, Mobile)	107	65	54	23
1. Routine	95	61	48	22
2. Follow-up	12	4	6	1
E. Licensed Establishment Plan Review	10	2	2	1
F. Enforcement Activities	0	0	0	0
G. # of Advanced Food Training Participants	25	28	0	0
ON-SITE SEWAGE DISPOSAL				
A. # of Permit Applications Issued	48	43	43	36
B. Parcels Evaluated	61	54	44	48
C. Inspections Conducted during and/or after construction	34	34	61	68
WATER QUALITY CONTROL (Private, Public, Non-Comm)				
A. # of Permit Applications Issued	45	38	38	31
B. # of Site Inspections of Completed Water Well Systems	18	15	27	31
C. # of Approvals Issued for Newly Completed Water Well Systems	3	15	13	18
NUISANCE ABATEMENT				
A. # of Complaints Submitted	15	9	12	15
1. Initial Visit	8	4	11	12
2. Follow-up Visit	3	4	14	14



CLINTON OFFICE

1307 E. Townsend Rd. Saint Johns, MI 48879-9036 Ithaca, MI 48847-1627 (989) 224-2195

GRATIOT OFFICE

151 Commerce Dr. (989) 875-3681

MONTCALM OFFICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

BOARD OF HEALTH:	Bruce DeLong	George Bailey	Phil Kohn
	David Pohl	Timothy Gay	Adam Petersen

Gratiot Lightning Strike Incident 151 Commerce Dr. Ithaca, MI 48847 June 29th, 2023

At approximately 6:55am on 06/29/2023 the Gratiot Branch Office of the MMDHD was struck by lightning. A large boom was heard followed by popping noises. The Gratiot County cleaning crew was coming into the office and saw the strike happen. Staff in the building noted the loud sound and proceeded to smell electrical smoke (no smoke was visible). The building's power went out and proceeded to go on generator power. Staff reported the incident to their supervisor who informed them to call 911 to report the issue. Gratiot County cleaning crew returned to their office where they contacted their supervisor and HR to receive further direction.

At this point Consumer's Energy sent out technicians for electrical and gas to ensure sure there were no issues. County maintenance was contacted and looked at the building to determine if there were any external damages. At 8:44 am the Ithaca Fire Chief arrived on site and did a walk through inside and out. No external damage or hot spots were noted in the building. County maintenance contacted an electrician to determine the state of the electrical panels in the building. They were in working order.

Around 1:55pm equipment damage was being reported to MMDHD management. The list of damaged equipment can be found in the table on the following pages. MMDHD management met to discuss the damaged equipment and next steps. It was determined that MMDHD would contact MMRMA and begin the steps of completing an insurance claim.

The building went back on normal power and county maintenance determined the generator would need additional repairs. They scheduled this for Friday June 30th. MMDHD IT staff were able to get internet back up and functional, but it was determined the new Fortinet switches were struck. MMDHD was able to utilize back up switches in the meantime until new ones could be ordered. In addition to this, staff docking stations, phones, printers, surge protectors, and a clinic computer had also been affected.

Furthermore, there was extensive damage to some clinic equipment including one of the new vaccine fridges. Immunization staff determined the fridge had gone out of temperature range and moved the stored immunizations to the Montcalm Branch Office. MMDHD reached out to the Michigan Department of Health and Human Services, Division of Immunizations, and the vaccine manufacturers to seek direction for the affected vaccine. This temperature excursion resulted in the loss of 17 doses with one needing to be replaced. Follet was contacted as the fridge was still under warranty and a vendor was dispatched to repair the fridge.



CLINTON OFFICE

1307 E. Townsend Rd. Saint Johns, MI 48879-9036 Ithaca, MI 48847-1627 (989) 224-2195

GRATIOT OFFICE

151 Commerce Dr. (989) 875-3681

MONTCALM OFFICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

BOARD OF HEALTH:	Bruce DeLong	George Bailey	Phil Kohn
	David Pohl	Timothy Gay	Adam Petersen

During this time the building HVAC system was determined to not be working in half of the building. The thermostats showed errors that would not clear. MMDHD reached out to county maintenance to request servicing. Additionally, one data drop in the office was not working. Maintenance requested Town and Country to come out to look at that drop.

As of 7/12/2023, MMDHD IT has submitted orders for the switches and docking stations, but they are not expected to arrive for 4-6 weeks. This will restore the connectivity to the office to its previous status. The clinic computer has been replaced and is functioning. Point broadband (internet provider) has been on site to remove damaged equipment and discussions regarding the tower outside of the building are taking place. The handicap accessible door has been fixed. RICOH printing has been restored to one of the printers in the office. RICOH is currently waiting on parts for the other 6 printers to arrive from Japan. They continue to come out when parts arrive. MMDHD's phone system is operational as it is a cloud-based system so staff can continue to answer calls using their agency issued computers or cell phones.

The Accense pods which monitor the vaccines that were affected have been sent back to the company for repair. In addition, the Follet fridge has been repaired and the lead care machine and scales have also been ordered and MMDHD is waiting for delivery. All vaccine has returned to the office and clinic operations are continuing with minimal disruption to clients. The remaining items will be ordered once approval from the insurance company has been granted. Currently MMRMA approved emergency items which are highlighted below.



CLINTON OFFICE 1307 E. Townsend Rd. Saint Johns, MI 48879-903 (989) 224-2195
1307 E. Townsend Rd.
Saint Johns, MI 48879-903
(989) 224-2195

GRATIOT OFFICE 151 Commerce Dr. 036 Ithaca, MI 48847-1627 (989) 875-3681

MOI	NTC/	ALM	OFF	ICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

BOARD OF HEALTH:	Bruce DeLong	George Bailey	Phil Kohn
	David Pohl	Timothy Gay	Adam Petersen

ITEM	DESCRIPTION	PRICE/EACH	COMMENTS
switches x2		\$8,217.54	CDW \$4108.77 each
phones x 25		\$7,609.95	Cisco 7841 - \$256.28 each x 18 = \$4,613.04 Cisco 8851 - \$428.13 each x 7 = \$2,996.91
docking stations x 18		\$5,894.79	Order 1023 CDW
imm/ppu monitor		\$923.68	CDW
printers		\$0.00	Waiting on estimates
point broadband router		\$0.00	covered by point broadband
surge suppressors x 30		\$600.00	approx. \$20 each
battery backup x2		\$4,497.22	2,248.61 each
office lamps tall black		\$38.55	
digital clock		\$38.79	
adult scale		\$370.00	
pediatric scale with power adapter		\$435.00	
zebra printer		\$580.65	
fish tank light		\$41.95	
lead care II	Magellen	\$2,000.00	already ordered by ruby

WWW.MMDHD.ORG — LIZ BRADDOCK, RS, MS Health Officer

JENNIFER MORSE, MD, MPH, FAAFP

er Medical Director



LIN I	ON (OFFI	CE	
L307 E.	Tow	nsen	d Rd.	

(989) 224-2195

151 Commerce Dr. Saint Johns, MI 48879-9036 Ithaca, MI 48847-1627 (989) 875-3681

GRATIOT OFFICE

MONTCALM OFFICE

615 N. State St. Stanton, MI 48888-9702 (989) 831-5237

BOARD OF HEALTH:	OF HEALTH: Bruce DeLong		Phil Kohn
	David Pohl	Timothy Gay	Adam Petersen

new follet fridge (likely just a new circupanel)	uit	\$0.00	fixed. Waiting on invoice from troubleshooters
K2		\$0.00	is working
thermostats		\$0.00	county is covering
handicap access button (outer door only)		\$253.00	door is fixed. Invoice is processing.
vaccines IPV & MMR	16 doses of vfc mmr does not need to be replace, vial of vfc ip does not need to be replaced	v \$200.00	estimated: only 1 dose of MMR at \$200. The VFC does not need to be replaced with private pay vaccine, therefore, no cost associated.
Samsung tablet mounted on wall in lobby	does not need to be replaced	\$200.00	vaccine, therefore, no cost associated.
accense pod/cord		\$215.00	These are to monitor vaccine temperature for refridgerators
8 port switch for accense		\$89.00	already replaced used Sarah's agency card to purchase in Alma

\$32,005.12 Total



MID-MICHIGAN DISTRICT BOARD OF HEALTH <u>ACTION ITEMS</u>

JUNE 2023

	JOINE 2023
The BOH authorized the MI from CDC Rural Health Initia	MDHD to spend an additional \$4,000.00 on the access control system with fund tiative Grant.



STAFFING REPORT – JULY 2023

Administration/Administrative Services Division

STATUS	POSITION	BRANCH OFFICE
ON HOLD	FT Data Specialist, Main Office effective date July 3, 2023	Main

Community Health and Education Division

STATUS	POSITION	BRANCH OFFICE
ON HOLD	PT (0.6 FTE) Hearing/Vision Technician, Montcalm Branch Office effective May 22, 2023	Montcalm
NEW HIRE	Abby Wease, PT (0.6 FTE) P.H. Representative, Clinton Branch Office effective July 10, 2023	Clinton

Environmental Health Division

STATUS	POSITION	BRANCH OFFICE
VACANCY	FT E.H. Specialist I/II, Montcalm Branch Office effective May 23, 2023	Montcalm



CLINTON • GRATIOT • MONTCALM

www.mmdhd.org

Mid-Michigan District Health Department July 2023 Newsletter

Happy July! As we continue to enjoy the summer months, whether it be vacations, staycations, or doing any activity we enjoy, I hope we all are having a great time. Summer activities mean there are a few things to keep in mind, which we will be highlighting in this July edition of the Newsletter. This month, we'll take a look at mosquitoes and the dangers they pose, Air Quality and the effects on our health, and also the importance of handwashing!

Lastly, results are in from the poll asking readers: What is your must have for summer cookouts? Find those below!

-Brady Guilbault, MMDHD Public Information Officer

Mosquitoes... More Than Just a Nuisance!

Almost everyone in the world has been bitten by a mosquito. Although most types of mosquitoes are just nuisance mosquitoes, some types of mosquitoes spread viruses that can cause disease.

Some mosquitoes like living near people, while others



prefer forests, marshes, or tall grasses. All mosquitoes like water because mosquito larvae and pupae live in the water with little or no flow.

Recently, 2 mosquito pools from Bay and Barry counties (2 total; 1 pool in each

county) tested positive for Eastern Equine Encephalitis virus (EEE). Human cases of EEE disease are rare but can cause serious illness, and in some cases death. There are no vaccines to prevent EEE infection in people and no specific treatments for EEE disease.

"This testing information confirms the virus is here in mosquitos in Michigan," said Dr. Natasha Bagdasarian, MDHHS chief medical executive. "EEE is one of the most dangerous mosquito-borne diseases in the United States, with a 33% fatality rate in people who become ill."

Read more by clicking below.

Learn more about EEE in Bay
County

How to Protect Yourself Against Mosquito Bites

- Use insect repellent: When used as directed, Environmental Protection Agency (EPA)-registered insect repellents are proven safe and effective, even for pregnant and breastfeeding women. Use an (EPA)-registered insect repellent with one of the following active ingredients:
 - DEET
 - Picaridin
 - IR3535
 - Oil of lemon eucalyptus (OLE)
 - Para-menthane-diol (PMD)
 - 2-undecanon
- Cover up: Wear long-sleeved shirts and long pants.
- **Keep mosquitoes outside:** Use air conditioning or window and door screens. If you are not able to protect yourself from mosquitoes inside your home or hotel, sleep under a mosquito bed net.


Air Quality and the Impacts on our Health

Climate change makes wildfire season worse. Hotter and drier conditions in North American forests mean that there is more dry wood and underbrush that can easily be ignited by a stray campfire spark or a lightning strike.

Wildfire smoke is made up of gases and small (or fine) particles that can harm your health if you breathe it. Everyone should avoid breathing wildfire smoke, and some people are more sensitive to it because of their age or pre-existing health conditions.

Learn more about what's in wildfire smoke at the Environmental Protection Agency's (EPA) page:

Why Wildfire Smoke is a Health Concern



Air Quality Index Levels of Health Concern	Numerical Value	Meaning
Good	0 to 50	Air quality is considered satisfactory, and air pollution poses little or no risk.
Moderate	51 to 100	Air quality is acceptable; however, for some pollutants there may be a moderate health concern for a very small number of people who are unusually senstive to air pollution.
Unhealthy for Sensitive Groups	101 to 150	Members of sensitive groups may experience health effects. The general public is not likely to be affected.
Unhealthy	151 to 200	Everyone may begin to experience health effects; members of sensitive groups may experience more serious health effects.
Very Unhealthy	201 to 300	Health Alert: everyone may experience more serious health effects.
Hazardous	301 to 500	Health warnings of emergency conditions. The entire population is more likely to be effected.

Note: Values above 500 are considered beyond the AQI. Follow recommendations for the "Hazardous" category.

Who is more sensitive to wildfire smoke?

Being sensitive to wildfire smoke means that you are at greater risk of experiencing a health effect if you breathe it, and that the effect may be more severe.

- Children
- Adults 65 and older

- Pregnant people
- People with heart disease, such as angina, heart failure, or abnormal heart rhythms
- People with lung conditions, such as asthma or chronic obstructive pulmonary disease (COPD)

Also, exercising or working outdoors increases the chance for harm, even if you are in good health. This is because the faster and deeper you breathe, as you would with exercise or physical labor, you increase the amount of wildfire smoke you take into your body. Likewise, the length of time you are outside increases the amount of smoke you are exposed to.

The Importance of Handwashing

Washing your hands is easy, and it's one of the most effective ways to prevent the spread of germs. Clean hands can help stop germs from spreading from one person to another and in our communities—including your home, workplace, schools, and childcare facilities.

Washing hands can keep you healthy and prevent the spread of respiratory and diarrheal infections. Germs can spread from person to person or from surfaces to people when you:

- Touch your eyes, nose, and mouth with unwashed hands
- Prepare or eat food and drinks with unwashed hands
- Touch surfaces or objects that have germs on them
- Blow your nose, cough, or sneeze into hands and then touch other people's hands or common objects

You can help yourself and your loved ones stay healthy by washing your hands often, especially during these key times when you are likely to get and spread germs:

- Before, during, and after preparing food
- Before and after eating food
- Before and after caring for someone at home who is sick with vomiting or



- diarrhea
- Before and after treating a cut or wound
- After using the toilet
- After changing diapers or cleaning up a child who has used the toilet
- After blowing your nose, coughing, or sneezing
- After touching an animal, animal feed, or animal waste
- After handling pet food or pet treats
- After touching garbage

If soap and water are not readily available, use a hand sanitizer with at least 60% alcohol to clean your hands.

"Handwashing is one of the best ways to protect yourself and your family from getting sick. If you are at the beach or any place where water and soap is not readily available you should use hand sanitizer with 60% alcohol. This is especially important before and after eating, after bathroom use, and changing of dirty diapers."

-Jennifer Johnson, RN, MMDHD Communicable Disease Nurse

Follow these five steps every time.

- 1. Wet your hands with clean, running water (warm or cold), turn off the tap, and apply soap.
- 2. Lather your hands by rubbing them together with the soap. Lather the
 - backs of your hands, between your fingers, and under your nails.
- 3. Scrub your hands for at least 20 seconds. Need a timer? Hum the "Happy Birthday" song from beginning to end twice.
- 4. Rinse your hands well under clean, running water.
- 5. Dry your hands using a clean towel or an air dryer.

What is your must have for summer cookouts?

Last month, I had polled readers of the question: What is your must have for summer cookouts? Myself, I go for the steak but I'm not going to complain if the most popular option is set out in front of me! Here are the results:

- 1. Burgers 34.8%
- 2. The Sides (Mac n' Cheese, Coleslaw, etc.) 19.6%



- 3. Hot Dogs 14.1%
- 4. The Desserts 12%
- 5. Steak 7.6%
- 6. Chicken 6.5%
- 7. Other 5.4%

Thank you everyone that participated!

Follow MMDHD on Social Media!









MID-MICHIGAN DISTRICT HEALTH DEPT. | 615 N State St, Stanton, MI 48888-9702

Unsubscribe lbraddock@mmdhd.org

<u>Update Profile</u> | Our Privacy Policy | Constant Contact Data **Notice**

Sent bybguilbault@mmdhd.orgpowered by



Try email marketing for free today!